

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72782 A3

- (51) International Patent Classification⁷: C07K 14/005, A61K 39/12, C07K 16/08
- (21) International Application Number: PCT/US01/08576
- (22) International Filing Date: 16 March 2001 (16.03.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/534,639 27 March 2000 (27.03.2000) US
09/692,170 20 October 2000 (20.10.2000) US
- (71) Applicant: CITY OF HOPE [US/US]; 1500 East Duarte Road, Duarte, CA 91010-3000 (US).
- (72) Inventor: DIAMOND, Don, J.; 415 N. Elwood Avenue, Glendora, CA 91205 (US).
- (74) Agents: FIGG, E., Anthony et al.; Rothwell, Figg, Ernst & Manbeck, P.C., Suite 701-E, 555 13th Street, N.W, Washington, DC 20004 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
25 April 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: IMMUNO-REACTIVE PEPTIDE CTL EPITOPES OF HUMAN CYTOMEGALOVIRUS

(57) Abstract: The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.

WO 01/72782 A3

INTERNATIONAL SEARCH REPORT

International Application No

P. /US 01/08576

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/005 A61K39/12 C07K16/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 19349 A (HOPE CITY) 22 April 1999 (1999-04-22) abstract disclosure page 49 examples claim 1	1-17,19
X	WO 97 40165 A (GONCZOL EVA ;WISTAR INST (US); BERENCSI KLARA (US); KARI CSABA (US) 30 October 1997 (1997-10-30) abstract disclosure example 3 figure 5	1-17,19
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

17 October 2001

Date of mailing of the international search report

08 February 2002 (08.02.02)

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No

P. /US 01/08576

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 00 75180 A (SUREL INGOLF PASCAL ;KERN FLORIAN (DE); KHATAMZAS ELHAM (DE); REIN) 14 December 2000 (2000-12-14) abstract page 27 claim 1	1-17,19
X	WO 98 26074 A (DAVIGNON JEAN LUC ;DAVRINCHE CHRISTIAN (FR); INST NAT SANTE RECH M) 18 June 1998 (1998-06-18) the whole document	17
X	WO 94 00150 A (HOPE CITY ;ZAIA JOHN A (US); PANDE HEMA (US); RIGGS ARTHUR D (US)) 6 January 1994 (1994-01-06) the whole document	17
X	PANDE H ET AL: "HUMAN CYTOMEGALOVIRUS STRAIN TOWNE PP65 GENE NUCLEOTIDE SEQUENCE AND EXPRESSION IN ESCHERICHIA-COLI" VIROLOGY, vol. 182, no. 1, 1991, pages 220-228, XP000561310 ISSN: 0042-6822 the whole document	1-17,19
X	PANDE H ET AL: "STRUCTURAL ANALYSIS OF A 64-KDA MAJOR STRUCTURAL PROTEIN OF HUMAN CYTOMEGALOVIRUS TOWNE IDENTIFICATION OF A PHOSPHORYLATION SITE AND COMPARISON TO PP65 OF HCMV AD169" VIROLOGY, vol. 178, no. 1, 1990, pages 6-14, XP001033533 ISSN: 0042-6822 the whole document	1-17,19
X	WILLS M R ET AL: "THE HUMAN CYTOTOXIC T-LYMPHOCYTE (CTL) RESPONSE TO CYTOMEGALOVIRUS IS DOMINATED BY STRUCTURAL PROTEIN PP65: FREQUENCY, SPECIFICITY, AND T-CELL RECEPTOR USAGE OF PP65-SPECIFIC CTL" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 11, 1 November 1996 (1996-11-01), pages 7569-7579, XP002060343 ISSN: 0022-538X the whole document	17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/08576

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-17,19 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.10 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

2. Claims: 1-19 (partially)

A peptide having sequence as in Seq.d.No.1, and its derivatives, sequences nos.2, 15,16, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

3. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos 3 and 4, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

4. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos.5 and 6, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

5. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos.7 and 8, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

6. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.No.9, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

7. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.11, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.12, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

9. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.13, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

10. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.Nos.14 and 44, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

11. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.17 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

12. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.18 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

13. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.19 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

14. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.20 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

15. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.21 and its use as an immunogenic antigen eliciting immune response against

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

human Cytomegalovirus; compositions and vaccines.

16. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.22 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

17. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.23 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

18. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.24 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

19. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.25 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

20. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.26 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

21. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.27 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

22. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.28 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

23. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.30 and its use as

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

24. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.31 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

25. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.32, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

26. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.33, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

27. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.34, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

28. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.35, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

29. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.36, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

30. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.37, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

31. Claims: 1-11, 13-17, 19 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A peptide having sequence as in Seq.d.No.38, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

32. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.39, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

33. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.40, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

34. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.41, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

P /US 01/08576

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9919349 A	22-04-1999	US 6156317 A	05-12-2000
		AU 7481498 A	03-05-1999
		EP 0946592 A2	06-10-1999
		EP 1023319 A1	02-08-2000
		JP 2001519181 T	23-10-2001
		US 6074645 A	13-06-2000
		WO 9821233 A2	22-05-1998
		WO 9919349 A1	22-04-1999
		US 6251399 B1	26-06-2001
-----	-----	-----	-----
WO 9740165 A	30-10-1997	AU 2809897 A	12-11-1997
		EP 0914441 A2	12-05-1999
		WO 9740165 A1	30-10-1997
-----	-----	-----	-----
WO 0075180 A	14-12-2000	DE 19927039 A1	07-12-2000
		DE 19943702 A1	08-03-2001
		AU 5963500 A	28-12-2000
		WO 0075180 A2	14-12-2000
-----	-----	-----	-----
WO 9826074 A	18-06-1998	FR 2757169 A1	19-06-1998
		AU 5489298 A	03-07-1998
		EP 0951554 A1	27-10-1999
		WO 9826074 A1	18-06-1998
		JP 2001506494 T	22-05-2001
-----	-----	-----	-----
WO 9400150 A	06-01-1994	CA 2117181 A1	06-01-1994
		WO 9400150 A1	06-01-1994
		AU 675204 B2	30-01-1997
		AU 2297292 A	24-01-1994
		DE 69232265 D1	17-01-2002
		EP 0605432 A1	13-07-1994
		JP 6510799 T	01-12-1994
		US 6207161 B1	27-03-2001
-----	-----	-----	-----

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/072782 A3

(51) International Patent Classification⁷: C07K 14/005,
A61K 39/12, C07K 16/08

(21) International Application Number: PCT/US01/08576

(22) International Filing Date: 16 March 2001 (16.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/534,639 27 March 2000 (27.03.2000) US
09/692,170 20 October 2000 (20.10.2000) US

CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

(71) Applicant: CITY OF HOPE [US/US]; 1500 East Duarte
Road, Duarte, CA 91010-3000 (US).

(88) Date of publication of the international search report:
25 April 2002

(72) Inventor: DIAMOND, Don, J.; 415 N. Elwood Avenue,
Glendora, CA 91205 (US).

(48) Date of publication of this corrected version:
3 April 2003

(74) Agents: FIGG, E., Anthony et al.; Rothwell, Figg, Ernst
& Manbeck, P.C., 1425 K Street NW, Suite 800, Washing-
ton, DC 20005 (US).

(15) Information about Correction:
see PCT Gazette No. 14/2003 of 3 April 2003, Section II

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: IMMUNO-REACTIVE PEPTIDE CTL EPITOPES OF HUMAN CYTOMEGALOVIRUS

(57) Abstract: The invention provides a plurality of peptides (and immunologically functional variants thereof) which are immunogenic epitopes recognized by CD8+ class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent human cytomegalovirus (HCMV) infection. The peptides are capable of activating CTLs and CTLps in the absence of active viral replication, and thus are useful for eliciting a cellular immune response against HCMV by normal and immunodeficient subjects. Peptide and lipopeptide vaccines, with and without adjuvants, also are disclosed. Cellular vaccines comprising the peptides form a further embodiment of this invention.

WO 01/072782 A3

IMMUNO-REACTIVE PEPTIDE CTL EPITOPES OF HUMAN CYTOMEGALOVIRUS**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH**

This invention was made with government support in the form of grant nos. CA30206,
5 CA77544 and CA33572 from the United States Department of Health and Human Services,
National Cancer Institute. The government may have certain rights in the invention.

BACKGROUND OF THE INVENTION1. Technical Field

10 This invention relates to human cytomegalovirus (HCMV), and in particular to peptide
fragments from one or more subunit proteins that function as T-cell epitopes of HCMV in
human beings. The peptides of this invention are capable of directing human cytotoxic T
lymphocytes (CTL) to recognize and lyse human cells equivalently to infection with HCMV.
Vaccines formulated using those peptides also are provided by this invention.

15 2. Description of the Background Art

The HCMV genome is relatively large (about 235k base pairs) and has the capacity to
encode more than two hundred proteins. HCMV is composed of a nuclear complex of double-
stranded DNA surrounded by capsid proteins having structural or enzymatic functions, and an
external glycopeptide- and glycolipid-containing membrane envelope. HCMV is a member of
20 the herpes virus family and has been associated with a number of clinical syndromes.

HCMV infection is relatively common and is usually self-limiting in the healthy,
immunocompetent child or adult (L. Rasmussen, Curr. Top. Microbiol. Immunol. 154:221-254,
1990), however, approximately 10% of all newborn infants carry HCMV and the virus can cause
severe congenital disease in the fetus or infant. Some of these newborn infants suffer congenital
25 birth defects. Other newborn infants carry cytomegalovirus for some time before they show
symptoms of disease. HCMV is a common cause of mental retardation in children who acquire
the infection in utero from mothers carrying an active infection.

Several studies have begun to question whether persistent and apparently asymptomatic
HCMV infection in an otherwise healthy adult poses health risks in certain individuals. For
30 example, individuals who have undergone coronary angioplasty sometimes subsequently develop
restenosis as a result of arterial remodeling. In one study, about one third of such patients with
restenosis had detectable HCMV DNA in their arterial lesions (E. Speir et al., Science 265:391-
394 (1994)). In another study, CMV seropositive patients were five times more likely to develop

restenosis than their seronegative counterparts (Y.F. Zhou et al., New England J. Med. 335:624-630 (1996)). These studies suggest that decreasing the number of HCMV infected host cells can benefit certain individuals.

HCMV also has been associated with morbidity and mortality in immunocompromised patients. HCMV is an important consideration in the treatment of patients suffering from Acquired Immunodeficiency Syndrome (AIDS). The defining complication is viral retinitis, which, if left untreated, can lead to blindness. Historically, CMV disease has been one of the more devastating of the opportunistic infections that beset HIV-1-infected individuals. Disease manifestations of CMV viremia which appear as the CD4⁺ T cell counts drops below 100/mm³ include encephalitis, enteritis and pneumonia. At autopsy there is multi-organ involvement of CMV disease in the preponderance of AIDS patients who had severe CMV retinitis. Patients infected with HCMV often suffer impairment of some of their vital organs, including the salivary glands, brain, kidney, liver and lungs. Furthermore, HCMV is associated with a wide spectrum of classical syndromes including mononucleosis and interstitial pneumonia. HCMV also has an oncogenic potential and a possible association with certain types of malignancies including Kaposi's sarcoma.

HCMV can cause opportunistic infections resulting in a variety of complications in, for example, immunosuppressed organ transplant patients. Prior to the use of antiviral chemotherapy, HCMV infection had been responsible for a substantial proportion of post-bone marrow transplantation (BMT) complications (J. Meyers et al., J. Infect Dis. 153:478-488 (1986)). The advent of drugs such as ganciclovir with substantial anti-HCMV activity dramatically reduced complications associated with post-BMT CMV infections (G. Schmidt et al. New England J. Med. 324:1005-1011 (1991); J.M. Goodrich et al., New England J. Med. 325:1601-1607 (1991)).

Ganciclovir is most effective when administered prophylactically before diagnosis of HCMV infection. This approach has several negative consequences, however, including a higher proportion of recipients becoming neutropenic (one third) and increased numbers of concomitant fatal bacterial and fungal diseases (J.M. Goodrich et al., Ann. Intern. Med. 118:173-178 (1993)). An alternative approach in which ganciclovir was given when HCMV antigens or DNA are first detected by culture methods provided no survival advantage compared to prophylaxis or treatment post-disease for all patients (D.J. Winston et al., Ann. Intern. Med. 118:179-184 (1993)). Finally, because of the acute nature of the side-effects, there is a need for increased

hospitalization and growth factor administration to treated patients which, coupled with the cost of ganciclovir prophylaxis, increases the cost of BMT after-care.

Because human cytomegalovirus is relatively common, yet is associated with extremely serious health conditions, a considerable effort has been made to study the biology of the virus with the aims of improving diagnosis of the disease as well as developing preventative and therapeutic strategies. The mounting of a CD8⁺ CTL response is believed to be an important mammalian host response to certain acute viral infections. The observations that HCMV infection is widespread and persistent, and can become reactivated and clinically evident in the immunosuppressed patient, suggest that virus-specific T-cells, including HCMV-specific CTL, play an important role in the control of persistent infection and in recovery from HCMV disease.

In humans, protection from the development of CMV disease in immunosuppressed BMT recipients correlates with the recovery of measurable CD8⁺ CMV-specific class I MHC-restricted T cell responses (Quinnan et al., New Eng. J. Med. 307:7-13 (1982); Reusser et al., Blood 78:1373-1380 (1991)). These observations led investigators to carry out clinical trials in which donor-derived HCMV-specific CD8⁺ CTL were infused into BMT recipients as an alternative to ganciclovir prophylaxis and therapy (S.R. Riddell et al., Science 257:238-241 (1992)). The transfer of CD8⁺ CTL clones to allogeneic bone marrow transplant recipients resulted in detectable CTL-based HCMV immunity, and statistically significant diminution of HCMV disease after BMT (E.A. Walter et al., New Eng. J. Med. 333:1038-1044 (1995)).

Although successful in application, this approach has the disadvantage that it requires a sophisticated laboratory setup (which is also highly labor-intensive and costly) to derive the HCMV-specific CTL *in vitro* for reinfusion into a patient. A desirable alternative would be to deliver a vaccine derived from HCMV that would impart immunity to a BMT recipient, a solid organ recipient, a heart patient, an AIDS patient or a woman of child-bearing years, without the need for *ex vivo* expansion of HCMV-specific CTL. No such vaccine presently is available, however. To develop such a vaccine, the viral peptide which cause the host to recognize HCMV in a protective manner must be identified, so that their amino acid sequence information can be determined.

The viral life cycle provides insight as to the most effective time frame for targeting a vaccine to maximally disrupt virus production and spread. Following HCMV entry into the host cell and uncoating, the viral genome is expressed sequentially via immediate early (0-2 hour), early (2-24 hour) and late (>24 hour) viral proteins. However, certain viral structural proteins such as pp65 are chaperoned into the cell because of their existence in large quantity in the viral

particle. Much attention has focused upon structural virion proteins as potential immunodominant target antigens for HCMV-specific CTL responses.

One viral structural protein, pp65, has been identified as a target antigen for CMV-specific class I MHC restricted CTL derived from the peripheral blood of most asymptomatic CMV seropositive individuals (E. McLaughlin-Taylor et al., J. Med. Virol. 43:103-110 (1994)). The Immediate Early (IE) protein is processed to form CTL epitopes which cause the stimulation of IE-specific CTL in many normal blood donors (F. Kern et al., J. Virol. 73(10):8179-8184 (1999); C. Retiere et al., J. Virol. 74(9):3948-3952 (2000); G. Zyulai et al., J. Infect. Dis. 181:1537-1546 (2000); F. Kern et al., Eur. J. Immunol. 30:1676-1682 (2000)). Nevertheless, it has not been shown that IE-specific CTL kill or lyse CMV-infected target cells similarly to CTL specific to structural proteins such as pp65 or pp150. Importantly, CD8⁺ class I MHC restricted CTL specific for pp65 will recognize autologous HCMV-infected cells without the requirement for viral gene expression, presumably as a result of processing of the internal depot of pp65 that is transferred into the cell during infection (M.J. Gilbert et al., J. Virology 67:3461-3469 (1993)). CTL against pp65 or pp150 (another matrix protein that is recognized frequently) are able to recognize and lyse HCMV-infected cells *in vitro* within an hour of infection in the absence of viral gene expression (S.R. Riddell and P.D. Greenberg, Curr. Top. Microbiol. Immunol. 189:9-34 (1994)). Thus, these CTL may represent an important effector cell for limiting HCMV reactivation and progression to CMV disease, and such a cellular immune response in both immunocompromised and normal individuals would be extremely important (C.-R. Li et al., Blood 83:1971-1979 (1994)). CTL recognizing envelope proteins are not a substitute for pp65 and pp150 CTL because they are rarely found, arising late in infection and they are poor lytic effectors because of the down-regulation of the required Class I MHC molecules (M.J. Gilbert et al., J. Virology 67:3461-3469 (1993)). Therefore, vaccines stimulating immunity against pp65 or pp150 may be the preferred mechanism for eliciting protective immunity against CMV infection.

Individual MHC Class I molecules preferentially bind peptides of a given motif. The amino acid sequence of specific positions of the motif are invariant, allowing a given peptide to bind to MHC Class I molecules with high affinity. These are referred to as "anchor positions" (K. Falk et al., Nature 351:290-296 (1991)). Amino acid positions other than the anchor positions also contribute to the specificity of peptide binding to MHC Class I molecules. Additionally, residues at positions within the CTL epitope which do not interact with MHC may nevertheless interact with T cells, presumably by binding the T Cell receptor (TCR). The binding of peptide amino acid residues to MHC or TCR structures is independently governed, so

that substitution of TCR binding amino acid residues in many cases will not interfere with binding to the MHC molecule on the surface of an antigen presenting cell.

Edman degradation followed by N-terminal sequence analysis has been used to sequence the peptide mixture which is bound to the MHC class I peptide binding groove. In most cases the length of these peptides is between 9 and 11 amino acids. Mass spectrometry of HPLC separated peptide mixtures can elucidate the primary sequence of individual peptides. Peptide fragments which bind to MHC identified in this manner are referred to as "naturally processed epitopes." Alternatively, one can predict which peptides of a given length, between 9-11 amino acids, will optimally bind to individual HLA Class I alleles based on their conformity to a motif (K. Falk et al., Nature 351:290-296 (1991)). One such motif has been established for HLA A*0201. Nonapeptide anchor residues are located at positions 2 and 9 for HLA A*0201, with minor contributions to binding from positions 1, 4, 3, 5, 6, 7, 8 in decreasing order of importance to binding strength (J.W. Drijfhout et al., Human Immunology 43:1-12 (1995)). Similar motifs have been established for decamers and undecamers for HLA A*0201. Correspondingly, unique amino acid motifs have been established for a subset of other HLA A and B alleles to predict binding peptides between 8-11 amino acids (H.G. Rammensee et al., Immunogenetics 41 (4):178-228 (1995)).

It is recognized that CTL are an important mechanism by which a mammalian organism defends itself against infection by viruses and possibly cancer. A processed form of, e.g., a viral protein minimal cytotoxic epitope (MCE) in combination with MHC Class I molecules is recognized by T cells, such as CD8⁺ CTL. Functional studies of viral and tumor-specific T cells have confirmed that an MCE of 8-12 amino acids can prime an antigen presenting cell (APC) to be lysed by CD8⁺ CTL, as long as the APC expresses on the cell surface the correct MHC molecule that will bind the peptide.

It has been shown that the route of entry of a protein into the cell determines whether it will be processed as an antigen bound to either MHC Class I or II molecules. The endogenous or Class I pathway of protein degradation is often used by infectious viruses when they are present within cells. Viral nucleoproteins which may never reach the cell surface as full length molecules are still processed within the cell, and degraded portions are transported to the surface via MHC Class I molecules. Viral envelope glycoproteins, merely because they are cell surface molecules, do not obligatorily induce CTL recognition. Rather, viral nucleoproteins, predominantly in the form of processed epitopes, are the target antigens recognized by CD8⁺ CTL (A. Townsend et al., Philos. Trans. R. Soc. Lond.(Biol) 323:527-533 (1989)).

Antigens entering the cell through exogenous pathways (pinocytosis, etc.) are not typically processed and presented by Class I MHC molecules. Therefore, methods to introduce proteins directly into the cytoplasm have become a focus of vaccine developers. An approach that has gained favor is to use recombinant vaccinia viruses to infect cells, delivering a large amount of intracellular antigen. The enthusiasm for using vaccinia viruses as vaccines has diminished, however, because these viruses have the potential to cause disease in immunosuppressed people, such as BMT recipients based on the Western Reserve strain. Another approach to vaccination is to mix an antigenic protein with an adjuvant and introduce the mixture under the skin by subcutaneous injection.

Yet another potential approach to immunization to elicit CTL is to use the MCE defined for a viral antigen in the context of a particular MHC restriction element to boost a CTL memory response to a virus. The ability of an MCE to provide protective immunity to challenge by a lethal dose of an infectious virus has been discussed in the literature. Vaccine developers have developed increasing interest in utilizing the MCE as the vaccine because it is capable of binding to MHC Class I molecules through external binding of the cell surface molecules without internalization or processing.

Historically, the MCE has been most effective as an immunogen when synthesized as a lipidated peptide together with a helper CD4 epitope (A. Vitiello et al., *J. Clin. Invest.* 95:341-349 (1995) and B. Livingston et al., *J. Immunol.* 159:1383-1392, 1997). Other modifications of the bispecific vaccine include inclusion of a signal sequence for endoplasmic reticulum retention and targeting (KDEL) to attain maximum activity. There is also evidence in the literature that an MCE presented by particular types of APC (e.g. dendritic cells) may cause a primary immune response to occur in the absence of viral infection or prior contact with the virus or tumor cell.

Introduction of CMV-specific CTL into a recipient is not a universally applicable and practical strategy to confer immunity to all those at-risk individuals who may need to be immunized against HCMV infection. Accordingly, in spite of significant efforts towards identifying the HCMV proteins that are recognized by CTLs, as well as the specific identification of the HCMV late structural protein pp65, improved methods of preventing and treating HCMV infection are needed.

SUMMARY OF THE INVENTION

Accordingly, one aspect of the present invention relates to immunologically active peptides, and functional variants thereof, capable of eliciting a cellular immune response to

HCMV in humans, *e.g.* SEQ ID NOS:10-25 and 30-41. The peptides are capable of directing human CTL to recognize and lyse human cells infected with HCMV. Such immunologically active peptides, in association with an MHC Class I molecule, are recognized by CTL of individuals having a latent (inactive) HCMV infection.

5 Another aspect of the present invention provides a method of augmenting the immune system of a patient in need thereof (*i.e.*, a patient harboring a latent or active CMV infection) by administering at least one immunologically active peptide or peptide derivative according to the present invention that will be recognized by CTL and/or CTLp (CTL precursors) of the patient.

In yet another aspect of the invention, at least one immunologically active peptide is
10 administered to uninfected individuals to provide immunity against future infections by HCMV. Such a peptide may be administered in the form of a peptide or lipopeptide vaccine, optionally with an adjuvant.

Alternatively, the peptide(s) may be administered in the form of a cellular vaccine via the administration of autologous or allogeneic antigen presenting cells or dendritic cells that have
15 been treated *in vitro* so as to present peptide on their surface.

Yet another aspect of the invention is a method to augment the immune response of an individual who is latently infected with CMV and is at risk for reactivation of CMV infection, wherein T cells are removed from an individual and treated *in vitro* with a peptide of the present invention. The resulting CMV-reactive CTL are reinfused autologously or allogeneically to the
20 patient, for example, a BMT recipient.

In yet another aspect, a method to confer immunity against an HCMV infection to a previously uninfected individual includes the steps of removing T cells from the individual, exposing the T cells *in vitro* to a peptide of the present invention and then reinfusing the resulting HCMV-reactive CTL to the individual.

25 The peptides of the present invention also may be administered to previously infected or uninfected patients, or *in vitro* to T cells, in the form of a polynucleotide (DNA-based) vaccine, wherein a suitable gene transfer vector, such as a plasmid or an engineered viral vector that contains DNA encoding the peptide fragment under the control of appropriate expression regulatory sequences, is administered to the patient or to T cells in culture.

30 In yet another of its aspects, the present invention provides a vaccinia, modified Vaccinia Ankara, canarypox or other eukaryotic virus vector containing a DNA sequence encoding the immunologically active peptide fragment, optionally including a helper CD4 epitope in the recombinant virus to stimulate and prolong CTL function. The vector infects an antigen

presenting cell which in turn presents antigen that will be recognized by CTLs of patients having a latent (inactive) HCMV infection.

An additional aspect of the invention relates to diagnostic reagents for detection of the presence of active versus quiescent HCMV infections. The peptides according to the present invention can directly stimulate CTLp *in vitro* and therefore can be used in an assay to determine the degree of immunostimulation being caused by HCMV. The peptides can also be used to distinguish individuals who are seropositive from those who are seronegative. T cells from a patient can be contacted *in vitro* with antigen presenting cells that have been primed with a peptide according to the present invention.

The invention includes peptides according to SEQ ID NOS:10-25 and 30-41 and vaccines comprising the peptides of SEQ ID NOS: 1, 10-25 and 30-41. Cellular vaccines also are provided, which comprise antigen presenting cells that have been treated *in vitro* so as to present a peptide according to any one of SEQ ID NOS: 1, 10-25 and 30-41. Further, the invention comprises a recombinant viral vector vaccine which expresses a gene encoding a peptide according to any one of SEQ ID NOS:1-14, 19, 26-28 and 30. In addition, a further embodiment comprises a method of modulating the immune response to human cytomegalovirus infection, comprising administering a vaccine as described above.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows the cytotoxic response elicited by peptides in the absence of lipidation.

FIG. 2 shows the cytotoxic response elicited by monolipidated peptides.

FIG. 3 shows the cytotoxic response elicited by dilipidated peptides.

FIG. 4 is bar graphs showing cytotoxicity of antigen presenting cells by immunized splenocytes after one (A), two (B) or four (C) *in vitro* stimulations.

FIG. 5 presents the results of chromium release assays for cells immunized with SEQ ID NO:37.

FIG. 6 presents the results of chromium release assays for cells immunized with SEQ ID NO:37.

FIG. 7 shows comparative cytotoxicity data for cells from mice immunized with 100 or 25 nmoles SEQ ID NO:37.

FIG. 8 compares the cytotoxicity data for cells immunized with SEQ ID NO:37 in different vaccine formulations.

FIG. 9 compares the effectiveness of vaccines containing SEQ ID NO:37 and differing concentrations of DMSO.

FIG. 10 compares cytotoxicity data from cells immunized with different vaccine formulations of SEQ ID NO:37.

5 FIG. 11 compares cytotoxicity data from cells immunized with 25 or 50 nmoles SEQ ID NO:37 with or without a booster immunization.

FIG. 12 compares cytotoxicity data from cells immunized with SEQ ID NO:37 in different formulations.

10 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A nonapeptide having the sequence NLVPMVATV (pp65₄₉₅₋₅₀₃) (SEQ ID NO:1) is an immunogenic epitope of pp65 from CMV laboratory strains AD169 and Towne and all wild type isolates examined to date. The epitope is recognized by CD8⁺ Class I MHC restricted cytotoxic T-lymphocytes of patients harboring latent CMV infection. The peptide is capable of activating
15 CTL in the absence of active viral replication, and thus is useful for augmenting the immune system of both normal and immunodeficient patients, as well as in the study of the Class I antigen processing pathway for HCMV proteins. The amino acid residues in positions 2 and 9 are the preferred residues at those positions for interaction with HLA A*0201 and certain subtypes of HLA A*02XX, where XX= subtypes 02-22 (J.W. Drijfhout et al., Human
20 Immunology 43:1-12 (1995)). Nonetheless, other less preferred amino acid residues may replace the preferred anchors, and the peptide can continue to exhibit the capacity to bind HLA A*0201 and certain subtypes of HLA A*02XX and to stimulate HCMV-specific CD8⁺ CTL.

Thus, in one aspect, the present invention provides an immunologically active peptide, capable of eliciting a cellular immune response to human cytomegalovirus infection, of the
25 preferred sequence:

NLVPMVATV (SEQ ID NO:1).

Sequence variants of the preferred peptide include peptides of the sequence NX₁VPMVATX₂
30 wherein X₁ is L, I, M, T or V, and X₂ is V, A, C, I, L or T (SEQ ID NO:2). The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the

immunological effects disclosed herein, for example AAKXVAAWTLKAAANLVPMVATV wherein X is cyclohexylalanine; SEQ ID NO:15 or (d)AAKXVAAWTLKAAANLVPMVATV where X signifies cyclohexylalanine (SEQ ID NO:16).

Other immunologically active peptides according to the present invention include the
5 peptides:

YSEHPTFTSQY (SEQ ID NO:3)

which binds to HLA A*01XX including A*0101 and subtypes thereof. Sequence variants of this
10 peptide include peptides of the sequence YXEHPTFTSQY wherein X is S, T or L (SEQ ID NO:4). The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

15

FVFPTKDVALR (SEQ ID NO:5)

which binds to HLA A*68XX including A*6801 and subtypes thereof. Sequence variants of this
peptide include peptides of the sequence FX₁FPTKDVALX₂ wherein X₁ is V or T and X₂ is L, R
20 or K (SEQ ID NO:6). The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

25 TPRVTGGGAM (SEQ ID NO:7)

which binds to HLA B*07XX including B*0702 and subtypes thereof. Sequence variants of this
peptide include peptides of the sequence TPRVTGGGAX wherein X is L, F, or M (SEQ ID
NO:8). The invention includes the construction and selection of other functional sequence
30 variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

FPTKDVAL (SEQ ID NO:9)

which binds to HLA B*35XX including B*3502, B*3504, B*3506 and other subtypes thereof with compatible peptide binding sites. The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

RPHERNGFTVL (SEQ ID NO:10)

which binds to HLA B*07XX including B*0702 and other subtypes thereof with compatible peptide binding sites. The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

SVLGPISGHVLK (SEQ ID NO:11)

which binds to HLA A*11XX including A*1101 and other subtypes thereof with compatible peptide binding sites. The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

PTFTSQYRIQGKL (SEQ ID NO:12)

which binds to HLA B*3801/2 and other subtypes thereof with compatible peptide binding sites. The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

EFFWDANDIY (SEQ ID NO:13)

which binds to HLA B*44XX including B*4402 and other subtypes thereof with compatible peptide binding sites. The invention includes the construction and selection of other functional sequence variants, which can be carried out by those skilled in the art based upon the present disclosure. The peptide or the structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

FTSQYRIQGKL (SEQ ID NO:14)

10

which binds to HLA A*24XX including A*2402 and other subtypes thereof with compatible binding sites. The invention includes the construction and selection of other functional sequence variants such as TFTSQYRIQGKL (SEQ ID NO:44), which can be carried out by those skilled in the art based upon the present disclosure. The peptide or structural variants disclosed herein also can be a functional part of a longer peptide which produces the immunological effects disclosed herein.

The following constructs exemplify peptide vaccines according to the invention and are not intended to be limiting:

20 AKXVAAWTLKAAANLVPMVATV (SEQ ID NO:17)
 dAKXVAAWTLKAAANLVPMVATV (SEQ ID NO:18)
 VSTIVPYIGPALNIAAANLVPMVATV (SEQ ID NO:19)
 AKXVAAWTLKAAAYLVPMVATV-NH₂ (SEQ ID NO:20)
 dAKXVAAWTLKAAAYLVPMVATV-NH₂ (SEQ ID NO:21)
 25 AKXVAAWTLKAAANLVPMVATV-NH₂ (SEQ ID NO:22)
 AKXVAAWTLKAAAYLVPMVASV-NH₂ (SEQ ID NO:23)
 AKXVAAWTLKAAANLLPMVASV-NH₂ (SEQ ID NO:24)
 AKXVAAWTLKAAASVLGPISGHVLK (SEQ ID NO:25)

wherein X = cyclohexylalanine and d = dextro.

30

Truncations of the pp65 (Diamond et al. 1997) protein expressed in vaccinia viruses were screened against pp65-specific T cell (CD8⁺) clones from HLA typed CMV-seropositive individuals (Walter et al., New Engl. J. Med. 333:1038-1044 (1995); McLaughlin-Taylor et al.,

J. Med. Virol. 43:103-110 (1994). To facilitate fine scale mapping of CTL epitopes, recombinant vaccinia viruses have been prepared that express pp65 fragments separated by 100-200 nucleotides throughout the pp65 gene, with both amino and carboxyl terminal deletions. When the region circumscribed by recombinant vaccinia viruses was no greater than 100 amino acids, a series of overlapping peptides were synthesized. A series of 15mer peptides from pp65, overlapping by three amino acids, were used to identify CTL epitopes. Longmate et al., Immunogenetics (2000). Screening a 100 amino acid stretch of pp65 in this way requires a total of 29 different peptides. Autologous and HLA mismatched Epstein-Barr virus transformed lymphocyte cell lines (antigen presenting cells) were sensitized with the screening peptides at a concentration of 50 μ M for 1-2 hours, washed and chromated. The relevant CTL clone was incubated with the lymphocyte cell lines sensitized with peptide, and a standard chromium release assay was performed to determine the sensitivity of lysis. Peptide(s) which successfully sensitized lymphocytes to lysis by the pp65-specific T cell clones were then further truncated, both at the amino and carboxyl termini and retested. These steps were repeated until the minimal cytotoxic epitope that corresponds to the HLA allele of the T cell clones used was defined. Exemplary epitopes of pp65 are shown in Table 6.

Using the methods outlined above, peptides suitable for vaccine production can be identified for T cell clones from individuals having a variety of haplotypes. In this way, a cocktail vaccine useful to vaccinate large multi-ethnic human populations may be created. If a vaccine has broad enough reactivity to be usable for at least 90% of most ethnic populations, it is suitable to be used for public health. A multi-epitope peptide vaccine against HCMV would be very beneficial to several different at-risk patient groups including transplant recipients, AIDS patients, and gestational fetuses, not all of whom have been HLA-typed.

Peptides according to the invention may be formulated as vaccines according to any suitable method. Naked peptides or lipidated peptides may be formulated in a suitable adjuvant or any other pharmaceutically acceptable carrier. Cellular vaccines may be prepared by any known method. HCMV peptides according to the invention may be administered alone, or together with a helper peptide such as the polyclonal helper T lymphocyte peptide, PADRE. The CTL epitope and HTL peptide may be administered together or separately, but it is preferable to administer them in close time proximity.

Alternative vaccines include fusions of the helper CD4 peptide epitope with the CTL epitope. The peptides may be fused in either order and may contain a linker sequence between them if desired. Examples of helper CD4 epitopes are the synthetic sequence PADRE (J.

Alexander et al., *Immunity* 1:751-761 (1994)) and tetanus-specific peptides, however any helper T lymphocyte peptide may be used. In some cases, these fusion peptides may not require additional covalent lipid modification or adjuvant when administered by the subcutaneous, intranasal, intraperitoneal or intravenous routes. Alternatively, single stranded DNA containing CpG motifs or any other adjuvant may be co-administered to provide increased activity of the fusion peptide when simultaneously provided at limiting concentration.

A preferred alternative is to join the antigenic peptide to PADRE such that the two sequences form a single peptide chain. PADRE may be positioned at the N- or C- terminus of the antigenic HCMV peptide, and a linker sequence may be positioned between the two sequences or in front of the N-terminal sequence, if desired. A preferred structure for this type of vaccine peptide is AAKXVAAWTLKAAANLVPMVATV wherein X signifies cyclohexylalanine (SEQ ID NO:15) or (d)AAKXVAAWTLKAAANLVPMVATV wherein X signifies cyclohexylalanine (SEQ ID NO:16).

Peptides of the invention may be lipidated or may lack lipids. Unlipidated peptides, whether incorporating a helper peptide sequence or not, are contemplated by the invention, as are monolipidated, dilipidated or trilipidated peptide vaccines. Suitable lipids which may be linked to the peptide sequence include, but are not limited to palmitic acid, stearic acid, myristic acid, lauric acid, capric acid, decanoic acid and the like. Lipids may be attached to the peptides at any location and by any convenient method known in the art.

Adjuvants may form part of the vaccine formulation. Adjuvants such as complete or incomplete Freund's adjuvant, aluminum hydroxide or the like are contemplated, however a preferred adjuvant, particularly for use in humans, is a DNA adjuvant. Single-stranded DNA adjuvants comprising specific sequences including Cytosine-phosphate-Guanosine (CpG) are known in the art and are contemplated for use with this invention. DNA adjuvants lacking these CpG sequences also are useful with the invention. An exemplary DNA adjuvant may comprise a 20mer of nucleotides with 2 CpG motifs, or any DNA oligomer, generally about 20 to about 25 nucleotides long. Increased stability of the sequence may be obtained by substituting phosphate groups in the nucleotide backbone with two groups to create a phosphoro-thioate backbone rather than a phosphoro-diester backbone.

Evaluation of HCMV peptide-specific human CTL responses may be performed in HLA-A2.1/k^b transgenic mice, a well-accepted animal model, as follows. The mice are injected with the vaccine preparation. A booster may be given 12 days later if desired. About one week after the final immunization, splenocytes are prepared from the spleens of immunized mice and

cultured. Lipopolysaccharide (LPS) blasts for *in vitro* stimulation of the immunized cells may be prepared aseptically from suspensions of unimmunized mouse spleen cells ($1.0-1.5 \times 10^6$ cells/mL) by addition of 25 $\mu\text{g/mL}$ LPS and 7 $\mu\text{g/mL}$ dextran sulfate. These cells are loaded with the same CTL epitope peptide as was used to immunize the transgenic mice to create
5 antigen-presenting cells. These antigen-presenting cells are used to stimulate the cultured splenocytes from the immunized transgenic mice *in vitro* approximately 12-14 days after the final immunization. A second *in vitro* stimulation, or further *in vitro* stimulations, may be performed if desired. A second stimulation is preferred, and may be performed 5-7 days after the first *in vitro* stimulation. About a week after the last *in vitro* stimulation, a chromium release
10 assay may be performed to test the ability of the immunized transgenic splenocytes to specifically recognize and kill either mouse or human target cells loaded with the antigenic peptide of the vaccine.

Example 1. Derivation of T-cell Clones

15 Methods for deriving T-cell clones from CMV seropositive individuals have been described in the literature (see above references). Forty to fifty milliliter samples of whole peripheral blood were obtained from CMV seropositive volunteers (detected by standard antibody methods). The white blood cells (WBCs) were separated using Ficoll-HyPaque (DuPont) density gradient centrifugation. The whole blood was first centrifuged for 10 minutes
20 at 1400 rpm in a tabletop centrifuge to reduce the number of red blood cells. The buffy coat was diluted to 12 ml with phosphate buffered saline (PBS), and 6 ml were layered on top of $\frac{1}{2}$ volume of Ficoll-HyPaque. The top layer was removed after centrifugation at 2000 rpm in a tabletop centrifuge for 15-30 minutes. The interface containing the WBC was removed, diluted in PBS and recentrifuged for 8-12 minutes at 1000 rpm, which caused the WBC to pellet. The cells were
25 again resuspended in PBS and washed as above one additional time. Four to five million WBC/ml were resuspended in T cell medium (TCM) with human serum obtained from pooled AB+ (blood group) CMV seronegative donors (HAB).

Example 2. Derivation of LCL Antigen - Presenting Cells

30 Simultaneously, an autologous antigen presenting cell line was prepared by Epstein Barr virus immortalization of PBL (see Current Protocols in Immunology, Unit 7.22, Wiley-Liss Press (1993)). Deriving the CTLs and antigen presenting cells from the same individual ensured HLA matching between the cell lines.

Example 3. In vitro Stimulation by HCMV

To initiate the *in vitro* stimulation of the WBC, a monolayer of autologous dermal fibroblasts obtained from the same volunteers as the WBC was established by plating the cells in 12-well plates at 10^5 cells/ml/well in DMEM-10% HAB for 24 hours. After 24 hours in culture
5 the fibroblasts were infected with CMV virions (AD169 or Towne strain) for 2 hours at a multiplicity of infection of between 1 and 5. The medium and virus were aspirated from the monolayer, and 1 ml of fresh DMEM-HAB was added. The monolayer was incubated in the medium for an additional 4 hours, following which time, the medium was aspirated. Two
10 milliliters of medium containing 8-10 million WBC were added per well containing CMV infected fibroblasts. The WBC and fibroblasts were cultured in RPMI-1640 (Irvine Scientific) containing 50 U/ml penicillin, 50 µg/ml streptomycin, 4 mM L-glutamine, 25 µM 2-mercaptoethanol, 10 mM HEPES and 10% HAB (TCM-HAB). This was termed the first stimulation, and the cells were co-incubated for seven days. TCM-HAB was replaced if it became spent, and the culture was expanded if there was vigorous cell growth.

15 The WBC were re-stimulated on day 7 by plating onto a fresh monolayer of HCMV-infected autologous fibroblasts prepared as described above. In addition, γ-irradiated (2500 rad) autologous PBL (5-fold over WBC) were added as feeder cells, and the medium was supplemented with recombinant IL-2 (10 IU/ml, Chiron-Cetus) on days 2 and 4 of this second stimulation. Wells which exhibit rapid cell growth require new medium containing IL-2 as the
20 medium became spent.

After 12-16 days in culture, the cells were harvested and assayed for recognition of CMV matrix proteins in a chromium release assay (CRA). The CRA was performed using antigen presenting cells as target cells which are autologous or HLA-mismatched to the T-cell clone. The cells were prepared by infection with recombinant vaccinia viruses containing the DNA for
25 HCMV proteins such as pp28 (pp28vac), pp65 (pp65vac) and ppl50 (ppl50vac) or wild-type virus strain WR.

After overnight infection, the antigen presenting cells were incubated with chromium-51, washed, and the assay was carried out as described in Current Protocols in Immunology, Wiley-Liss Press, Unit 7.17, (1993). In the CRA, the vaccinia-infected target cells were loaded with
30 chromium-51 and then mixed with cells from the T-cell clone (effector cells). The cells were mixed at a series of effector : target cell ratios varying from 20:1 to 1:1. After a 4 hour incubation period, the medium in which the cells were incubated was harvested. The release of radioactivity into the medium (R_e) was quantitated with a gamma scintillation counter. The

extent to which infected antigen presenting cells exhibit spontaneous lysis and the release of radioactivity (R_s) in the absence of CTL was established for each virus vector. The maximum amount of radioactivity incorporated into and releasable by the target cells (R_{max}) was established by lysis of target cells in a detergent (1% Triton X100; Sigma) solution. Percentage cytotoxicity

5 was expressed as:

$$100 \times ((R_s) - (R_s)) / ((R_{max}) - (R_s)).$$

Assays were deemed unacceptable and were repeated unless spontaneous release (R_s) was less
10 than 30%.

Analysis of the assay was as described, with a positive result indicated by specific recognition of pp65vac infected autologous APC. A positive result for pp65 indicated that, in the tested polyclonal population, there were T cells which recognize the pp65 HCMV protein expressed by the virus.

15

Example 4. Procedure for Identification of the CTL Epitope

WBC stimulated two times by HCMV on dermal fibroblasts were cloned by limiting dilution in 96 well U-bottom plates as follows. After two HCMV stimulations, the WBC were depleted of CD4⁺ T cells by negative selection using incubation with paramagnetic beads
20 conjugated to anti-CD4 antibodies. The resulting population was generally between 90-95% CD8⁺, a reliable T cell subset marker, and generally 99% CD3⁺, a marker for most peripheral blood T cells as assayed by either flow cytometry or fluorescence microscopy. This final population was plated at a concentration between 0.3-3 cells per well in a final volume of 150 μ l. Each well also contained γ -irradiated $1.0\text{-}3.0 \times 10^5$ allogeneic peripheral blood mononuclear
25 cells (PBMC) in TCM-HAB supplemented with 50-100 IU/ml recombinant IL-2 (Chiron-Cetus) and 0.5 μ g/ml PHA (Murex).

After 3 days of culture, the PHA was diluted 2-fold by exchanging 75 μ l with fresh culture medium supplemented with rIL-2. The wells were supplemented with fresh rIL-2 every 3-4 days, and medium was replaced as necessary. The cells were restimulated 12-14 days later
30 with fresh allogeneic PBMC as described above, and the plates were carefully observed for growth in individual wells. Visible cell growth indicated the need to transfer the expanding T cells to larger wells. T cells were restimulated every two weeks, and were transferred to progressively larger wells. At the stage of accumulation of several million cells, some were

cryopreserved, and others were subjected to a further CRA. In this CRA, the targets were HCMV infected fibroblasts, uninfected fibroblasts, or autologous LCL infected with wild type vaccinia or vaccinia virus expressing either pp28, pp65 or pp150. HLA mismatched fibroblasts and LCL were used as controls. One T cell clone among several tested, which was designated 3-3F4, had the characteristics of being both CMV and pp65-specific, and was reactive only to autologous targets in a specific manner. Other T cell clones with different HLA phenotypes were initially isolated in the same way, except that the initial peripheral blood sample came from different volunteers.

The HLA element which restricted the recognition of the T cell clone 3-3F4 to pp65 was identified. A series of LCL were used as targets that were singly autologous with each HLA allele of the 3-3F4 cell line. Each target was separately infected with pp65vac, wild type vaccinia, or not infected at all. The results showed that only the LCL that were autologous to the HLA A*0201 allele were being recognized and killed by the 3-3F4 T cell line. It was also established that 3-3F4 is of the CD8⁺ T cell subset, characteristic of CTL which recognize Class I restricted peptides. Whether the cell line was monoclonal was tested by carrying out PCR repertoire analysis using a series of 26 human V β gene segment primers. Only one of 26 primers gave a significant signal, the V β 13.1 primer, thereby demonstrating the apparent monoclonality of the 3-3F4 T cell clone.

To identify the precise epitope or peptide recognized by the T cell clone 3-3F4, a series of vaccinia truncations that deleted the pp65 protein from the carboxyl towards the amino terminus was used. A CRA was conducted utilizing autologous and HLA mismatched LCL targets infected with vaccinia viruses expressing truncation products of the pp65 protein. This experiment localized a region between amino acids 377 and 561 that was necessary for killing of targets. Utilizing a small subset of amino terminal deletions, the region necessary for killing was further localized between amino acids 477 and 561. Utilizing an indirect killing assay, a monkey kidney cell line was transfected with the molecular HLA allele HLA A*0201 and portions of the pp65 gene to localize the region to a fragment containing amino acids 452-561. The final determination of the peptide sequence that corresponds to the sequence bound by HLA A*0201, and is recognized by T cell clone 3-3F4 was done by producing 9-10 amino acid peptides on a Synergy (Applied Biosystems Model 432) peptide synthesis machine. Using published information, a series of candidate sequences were determined that had significant characteristics of an HLA A*0201 binding sequence, and were located in the region between amino acid 452-561. These were:

Table 1			
Amino Acid Sequence of Peptide	Position Number	Motif	Score*
ILARNLVPMV (SEQ ID NO:26)	491	A*0201	67
ELEGVWQPA (SEQ ID NO:27)	526	A*0201	59
RIFAELEGV (SEQ ID NO:28)	522	A*0201	55
NLVPMVATV (SEQ ID NO:1)	495	A*0201	63

5
10 *(adapted from J. D'Amato et al., "A computer program for predicting possible cytotoxic epitopes based on HLA Class I peptide binding motifs," Human Immunology 43:13-18 (1995)).

Only one of these peptides (referred to as "the 495 peptide" or as "pp65₄₉₅₋₅₀₃") (SEQ ID NO:1) proved capable of priming the autologous LCL to be recognized and killed by the CD8⁺ CTL 3-3F4. Other 9-10 amino acid peptides from pp65 that also followed the HLA A*0201 motif were
15 tested in the CRA. None showed any activity. All peptides were examined for purity by HPLC on a Vydac C₁₈ column using acetonitrile/TFA as the moving phase. They were 70-80% pure or greater on average, and were used as dilutions from 0.1% acetic acid solution.

Example 5. Use of the 495 Peptide To Induce Cell Lysis

20 Serial dilutions of the 495 peptide showed no change in activity between 10 μ M and 0.01 μ M in priming autologous LCL for killing by T cell clone 3-3F4 in a CRA. Half-maximal lysis occurred at close to 0.5 nM peptide. The peptide-transporter deficient cell line T2 (D.B. Crumpacker et al., J. Immunol. 148:3004-3011 (1992)), which is HLA A*0201 positive, also was
25 used to test the lower limits of sensitivity of the 3-3F4 T cell clone for recognition of the peptide in a CRA. It was found that as little as 0.1 nM peptide caused maximal lysis of T2 cells, equivalent to the condition with 10 nM peptide. These experiments demonstrate that this minimal cytotoxic epitope is a strong binder to the HLA A*0201 allele.

The 495 peptide depicted in Table 1 was prepared on a Synergy (Applied Biosystems Model 432) peptide synthesis machine. Dermal fibroblasts were primed with the peptide, then
30 loaded with chromium-51 by incubation with 10 μ M of the 495 peptide for 2 hours at 37° C, and for the final hour with chromium-51. The peptide and chromium-51 were washed out of the medium.

T cell clone 3-3F4 (CD8⁺ CTL), derived from an HCMV seropositive individual (HLA A*0201 positive) was capable of recognizing the HCMV-infected fibroblasts as well as the peptide-primed fibroblasts in a CRA. Uninfected and unprimed fibroblasts were not recognized or killed by the T cell clone. In addition, an HLA-mismatched fibroblast line without the HLA A*0201 allele found on the donor fibroblasts was not recognized or killed by the T cell clone when it was either infected by HCMV or primed with the 495 peptide. Thus, the 495 peptide of the present invention can serve as a substitute for the whole HCMV virus, causing normal T cells to recognize and kill fibroblasts as effectively or better than if they were infected with HCMV.

10 Example 6. Generation of TNF- α by T Cell Clones

TNF- α is a T cell lymphokine that is cytotoxic for many cell types and may contribute to the *in vivo* immune response mounted against an HCMV infection. Cells of the 3-3F4 T cell clone were incubated with autologous fibroblasts pre-incubated with either whole HCMV virions or primed with the 495 peptide of Table 1. Twenty four hours later, supernatants from the co-incubated cells were applied to an indicator cell line in a bioassay as described above. The indicator cell line, a WEHI derivative, is sensitive to the cytotoxic action of TNF- α at the picomolar level.

Peptide-primed fibroblasts induced the production of as great or greater levels of TNF- α from T cell clone 3-3F4 as were the HCMV-infected fibroblasts. The peptide of SEQ ID NO:1 did not induce TNF- α production by either autologous fibroblasts incubated without T cells or non-HLA-A*0201 expressing fibroblasts incubated with the T cell clone.

Example 7. Peptide SEQ ID NO:1 Can Induce CTL From PBL of HCMV Seropositive Individuals

25 PBL from HCMV-seropositive individuals were plated onto SEQ ID NO:1 peptide-primed autologous fibroblasts or incubated with irradiated autologous PBL sensitized with SEQ ID NO:1 peptide for seven days. The once-stimulated PBL were re-stimulated in a similar manner, either with or without depletion of CD4 T cells. After two weeks, a chromium release assay was performed using as targets either peptide-primed, CMV-infected, or untreated autologous fibroblasts. CD8⁺ T cells lysed significant percentages of the peptide-primed and HCMV-infected fibroblasts or EBV-LCL primed with SEQ ID NO:1, but not untreated cells. No autologous fibroblast targets were lysed by CD4-depleted PBL from freshly drawn blood under the same conditions. Experiments were repeated with T cells from 15 healthy adult volunteers.

In all but one case, donor possessing a matching HLA allele had T cells which responded to SEQ ID NO:1. Similar experiments were conducted with HIV patients, without *in vitro* stimulation of the T cells. The majority of HIV positive donors with a matching HLA allele also possessed T cell clones which could recognize autologous EBVLCL primed with SEQ ID NO:1.

5

Example 8. Human Cell Lines Which Express HLA A2, With Molecular Subtypes Other Than A*0201, Are Sensitized to Lysis by The 495 Peptide

Twelve cell lines were subjected to chromium release assays in which they were pulsed with the 495 peptide (pp65₄₉₅₋₅₀₃) nonamer, loaded with chromium-51, and incubated with two different HLA A*0201 restricted CTL which recognize the 495 peptide and HCMV. The specific cytotoxicity was calculated and is shown in tabular form below for the 1 μ M and 1 nM concentrations of the 495 peptide. A plus sign (+) represents cytotoxicity greater than 30%, a plus/minus sign (+/-) represents cytotoxicity between 5% and 30%, and a minus sign (-) represents cytotoxicity less than 15%.

15

Table 2				
HLA A2 Subtype	CTL 3-3F4		CTL VB-57	
	1 μM	1nM	1 μM	1nM
A*0201	+	+	+	+
A*0202	+	-	+	-
A*0203	+	-	-	-
A*0204	+	+	+	+
A*0205	+	-	+	+
A*0206	+	+	+	+
A*0207	+	+	+	+
A*0209	+	-	+	-
A*0210	+	+	+	+
A*0211	+	-	+	+/-
A*0217	+	-	+	+

20

25

30

The data showed that all tested subtypes functionally bound the 495 peptide at 1 μ M, and the cell lines were lysed by the HCMV and pp65 specific CTL. These data also showed that the cell line

subtypes shown here were capable of being sensitized for lysis by the 495 peptide. The data also indicate that cells from individuals who carry these subtypes can be sensitized by the peptide for CTL recognition and lysis, albeit at a higher concentration in most cases than what was found for HLA A*0201. Thus, individuals who carry any of these HLA A2 subtypes can respond to the

5 495 peptide as a vaccine.

Example 9. Animal Studies Using The495 Peptide (SEQ ID NO:1)

A transgenic mouse model lacking prior HCMV exposure, the HLA A2.1 mouse (E.J. Bernhard et al., J. Exp. Med. 168:1157-1162 (1988)), was employed to test whether the 495

10 peptide could stimulate CTLs lacking prior virus exposure and function as a vaccine. These experiments involved *in vitro* analysis using mouse and human cell targets, either infected with viruses or primed with the peptide of SEQ ID NO:1 or a non-specific control peptide.

Three mice were immunized subcutaneously at the base of the tail with 50 µg of the 495 peptide (pp65₄₉₅₋₅₀₃) or peptide p53₁₄₉₋₁₅₇ from p53 (M. Theobald et al., Proc. Natl. Acad. Sci. U.S.A. 92:11993-11997 (1995)) together with 20 µg of the polyclonal helper T lymphocyte

15 (HTL) peptide (PADRE; SEQ ID NO:29) (J. Alexander et al., Immunity 1:751-761 (1994)) emulsified in IFA (Incomplete Freund's Adjuvant). After twelve days, spleens were removed from immunized mice, a splenic suspension was made, and the effector cells were restimulated for one week using p53₁₄₉₋₁₅₇ or pp65₄₉₅₋₅₀₃ peptide sensitized syngeneic lipopolysaccharide-

20 treated splenic blast cells (P.A. Wentworth et al., Eur. J. Immunol. 26:97-101 (1996)). Thereafter, for subsequent *in vitro* stimulations, the stimulator cells were Jurkat A2.1 cells, prepared by mild acid treatment and subsequent loading of peptides (Z. Yu et al., Journal of Surgical Research 69:337-343 (1997)). After two *in vitro* restimulation cycles, the murine splenic effector population was tested for recognition of p53₁₄₉₋₁₅₇ or pp65₄₉₅₋₅₀₃ peptide loaded T2

25 cells. There was substantial recognition of pp65₄₉₅₋₅₀₃ or p53₁₄₉₋₁₅₇ peptide in mice that had been appropriately immunized, without recognition of the non-immunizing peptide.

It was also demonstrated that murine splenic effectors recognize endogenously processed pp65 in a chromium release assay with human HLA A*0201 EBVLCL targets infected with pp65Vac (D.J. Diamond et al., Blood 90 (5):1751-1767 (1997)). Further proof that the pp65₄₉₅₋₅₀₃

30 peptide causes recognition of virus-infected cells came from a chromium release assay using HCMV-infected human fibroblasts as targets, and murine CTL derived from the pp65₄₉₅₋₅₀₃ peptide stimulation as the effector population. HLA A*0201 fibroblasts infected with HCMV were capable of lysis by the CTL, whereas both uninfected and mismatched fibroblasts were not

recognized (D.J. Diamond et al. Blood 90 (5):1751-1767 (1997)). Taken together, these results clearly showed that the splenic effector population from a primary immunization with pp65₄₉₅₋₅₀₃ are recognized endogenously processed pp65 and HCMV in an HLA A*0201 restricted manner.

An additional study demonstrated that the 495 peptide induced a long-lived immune response in animals. Twelve mice were simultaneously immunized with the 495 peptide (SEQ ID NO:1) + PADRE (AKXVAAWTLKAAA; SEQ ID NO:29) + IFA, and two additional control mice were immunized with PADRE + IFA alone. At two weeks, 6 weeks, 10 weeks and 14 weeks after the immunization, the spleens from two immunized mice were analyzed for immunity against the 495 peptide or a control peptide from human p53 (p53₁₄₉₋₁₅₇). In addition, at two and six weeks, mice immunized without the 495 peptide also were sacrificed and their spleen cells analyzed for immune responses against the 495 peptide or the human p53 peptide. Percent specific cytotoxicity (cytotoxicity of 495 peptide targets - cytotoxicity of p53 targets) was still at a level of 40% after 14 weeks, whereas naive animals did not show any specific cytotoxicity above 5%. This compared well with recent results from immunizing human volunteers with the Theradigm™ lipopeptide (B. Livingston et al., J. Immunol. 159:1383-1392 (1997)) in which there was an average maintenance of 60% of the initial response 38 weeks after the final of four immunizations over an eighteen week period.

Example 10. Lipidated Peptides Incorporating pp65₄₉₅₋₅₀₃ (SEQ ID NO:1) as IFA-Adjuvant Independent Vaccines in Animals

Although the use of adjuvants to enhance immunogenicity is a common strategy in animal studies, there are important limitations concerning their use in humans. Therefore, one embodiment of the present invention involves peptides which incorporate lipid molecules. This strategy has been efficacious in both animal (K. Deres et al., Nature 342:561-564 (1989)) and human clinical studies (A. Vitiello et al., J. Clin. Invest. 95:341-349 (1995)) to avoid having to use adjuvants.

Either one or two palmitic acid moieties were attached to the amino terminus of the 495 peptide, and a series of immunization studies were conducted in the transgenic HLA A2.1 mouse. The primary structure of the directly lipidated peptides is shown in Table 3.

Table 3. Primary Structure of Peptides Used to Immunize HLA A2.1 Transgenic Mice				
Lipid Molecule(s)	Adaptor Sequence	Epitope Sequence (SEQ ID NO:1)	Carboxyl Terminus	SEQ ID NO:
0	-KSS-	-NLVPMVATV-	OH	30
1 PALMITIC ACID	-KSS-	-NLVPMVATV-	OH	31
2 PALMITIC ACID	-KSS-	-NLVPMVATV-	OH	32

Table 3. Peptides were synthesized on the ABI 432 (Applied Biosystems), and purified and analyzed as described (D.J. Diamond et al., Blood 90 (5):1751-1767 (1997)). Palmitic acid (Aldrich) was dissolved in dimethylformamide, and automatically coupled to the amino terminal lysine. The amino terminal lysine of the monolipidated form of the peptide was protected by two protecting groups, Fmoc and Boc. Only the Fmoc group is cleaved during synthesis to allow for a single lipid moiety to be added. For the dilipidated form, the amino terminal lysine was protected with two Fmoc groups, therefore allowing two lipid moieties to be added. Peptides also may be lipidated at other locations by methods well known in the art and are contemplated for use here.

Separate mice were immunized with unmodified pp65₄₉₅₋₅₀₃, and either the monolipidated or dilipidated forms of the peptide together with the PADRE epitope. Because it has been previously shown that lipidated peptides will stimulate immunity without co-administration of Freund's adjuvant (H. Schild et al., Eur. J. Immunol. 21:2649-2654 (1991)), immunization of mice with and without emulsifying the peptides in IFA was compared. In a procedure similar to the procedure described in Example 9 above, twelve days post inoculation the mice were splenectomized and the spleen cell population was restimulated twice *in vitro*. The splenic effectors were then tested in a chromium release assay with peptide-loaded T2 cells, EBV-LCL targets infected with pp65Vac, and HCMV-infected fibroblasts (D.J. Diamond et al., Blood 90 (5):1751-1767 (1997)). The results demonstrate that the lipidated form of the 495 peptide, without emulsification in adjuvant, induces an immune response capable of recognizing endogenously-processed pp65 and HCMV-infected human cells. The monolipidated form appeared to induce a weaker immune response (compare with and without IFA), whereas the unmodified free peptide had no activity unless emulsified in IFA. (See Figs. 1-3)

These data illustrate an advantageous immunization/vaccination procedure for use in warm blooded animals, including humans. The procedure entails the mixture of two peptides in an aqueous solvent system (the lipidated 495 peptide plus either PADRE or the 830-843 amino acid tetanus peptide, Table 3). The mixture is administered subcutaneously or via another acceptable and efficacious route to either HCMV seropositive or seronegative subjects. An additional set of booster injections may be employed to enhance the immunity induced by primary vaccination.

Example 11. Formulation of Lipidated Vaccines

The 495 peptide and functional sequence variants thereof can be formulated as a vaccine as a lipidated peptide with a covalent HTL epitope. The HTL epitope can be any peptide that has broad reactivity to human MHC class II to stimulate a classic helper response. Such molecules include but are not limited to amino acids 830-843 from tetanus toxin (P. Panina-Bordignon et al., Eur. J. Immun. 19:2237-2242 (1989)), HTL epitopes from HIV envelope protein (J.A. Berzofsky et al., J. Clin. Invest. 88:876-884 (1991)), or a synthetic version (PADRE) predicted from known anchor residues (J. Alexander et al., Immunity 1:751-761 (1994)).

The lipidation of the HTL+CTL epitope preferably is performed on the amino terminus of the HTL epitope, with the HTL epitope being amino terminal to the CTL epitope. Suitable lipid moieties are known and described in the literature. (H. Schild et al., Eur. J. Immunol. 21:2649-2654 (1991); A. Vitiello et al., J. Clin. Invest. 95:341-349 (1995); K. Deres et al., Nature 342:561-564 (1989)). Alternatively, the CTL epitope can be lipidated at its amino terminus, followed by the HTL epitope, or the lipid can be found at the carboxyl terminus followed by either the CTL or HTL epitope(s). A three amino acid spacer or any other spacer can be inserted between the HTL and CTL epitope, or the epitopes can be fused directly in frame. Alternatively the CTL epitope lipidated on its amino terminus can be administered together with the HTL epitope, without covalent attachment. The vaccine epitopes, regardless of primary structure, may be injected s.c. into the forearm in a standard formulation buffer (e.g., PBS or PBS/10% DMSO or higher concentration/0.01% trifluoroacetic acid or other acid or alcohol of the same or different concentration) once. Three to six weeks later, a booster injection of the same material may be administered. Multiple booster injections spaced three to six weeks apart can be subsequently administered, if necessary.

This injection series can be administered to a patient or at-risk individual, or to the donor of a bone marrow transplant, who is either positive or negative for the virus. Illustrative examples of lipidated vaccine peptides include, for example:

Table 4

<u>N-terminal</u>	<u>C-terminal</u>
(Pam) ₂ -KSS <i>QYIKANSKFIGITE</i> <u>AAA</u> NLVPMVATV (SEQ ID NO:33)	
(Pam) ₃ -CSS <i>QYIKANSKFIGITE</i> <u>AAA</u> NLVPMVATV (SEQ ID NO:34)	
(Pam) ₂ -KSSAKXVAAWTLKAAAGGGNLVPMVATV (SEQ ID NO:35)	
(Pam) ₃ -CSSAKXVAAWTLKAAAGGGNLVPMVATV (SEQ ID NO:36)	

10

wherein X is cyclohexylalanine or phenylalanine. As is the case throughout, all amino acids are represented by their universal one-letter code. "Pam" is palmitic acid. The three-A or -G spacer (underlined) can be interchanged among vaccine peptides. The format of the peptides shown above can be described (from the amino terminus) as: lipid-K/CSS--HTL epitope (italics)--amino acid spacer (underlined)--CTL epitope. The positions of the CTL and HTL epitopes may be interchanged. The CTL epitope (or a functional sequence variant thereof) may be further modified by adding a leader sequence and/or the amino acids KDEL can be appended to the carboxyl terminus to enhance retention and targeting into the endoplasmic reticulum. Palmitic acid or any suitable lipid may be used, including but not limited to stearic acid, myristic acid, lauric acid, capric acid and decanoic acid.

15

20

Example 12. Use of Combined HTL and CTL Epitope, Lipidated at the Amino Terminus, as a
Single Component Vaccine in Transgenic Mouse Studies

Two further molecules, each containing lipid, HTL and CTL epitopes, were constructed and tested in mice:

25

Table 5

<u>N-terminal</u>	<u>C-terminal</u>
A. (Pam) ₂ -KSSAKXVAAWTLKAAANLVPMVATV (SEQ ID NO:37)	
B. (Pam) ₂ -KSSISQAVHAAHAEINEAAANLVPMVATV (SEQ ID NO:38)	

30

Nomenclature for Table 5 can be found in the legend to Table 4.

Molecule A (SEQ ID NO:37) is a vaccine that has the capability of working in mice and humans, whereas molecule B (SEQ ID NO:38) should only be functional in mice. One hundred nanomoles of each of these vaccine peptides in 25% dimethylsulfoxide in phosphate buffered saline with 2.5% hexafluoroisopropanol were injected s.c. into separate transgenic HLA A2.1 mice.

The methods referred to in Examples 9 and 10 were used to derive spleen cell populations containing cells which were specific against pp65 and HCMV. The spleen cells from immunized mice were tested for recognition and cytotoxicity against specific and non-specific peptide-sensitized targets, HCMV infected and non-infected HLA A*0201 and HLA-mismatched fibroblast targets. The 495 pp65₄₉₅₋₅₀₃ peptide sensitized targets were effectively lysed, whereas targets sensitized with a peptide derived from another protein (human p53) which binds to HLA A*0201 (p53₁₄₉₋₁₅₇) were ineffective. In addition, and importantly, HCMV-infected HLA A*0201 fibroblasts were effectively lysed, but uninfected fibroblasts or those which are HLA-mismatched were not recognized or lysed, regardless of HCMV infection. These results were obtained with both molecules A and B, although molecule A was the more potent of the two. However, a second immunization (booster) of mice immunized with Vaccine A at lesser amounts of 50 nmole resulted in a detectable immune response when a single immunization was not effective (Table 5). This stimulative effect of the booster is in agreement with B. Livingston et al., *J. Immunol.* 159:1383-1392 (1997)). These data showed that the single molecule form of the vaccine functions to stimulate HCMV immunity in an animal model without any added molecules or adjuvant other than the vaccine molecules A or B (Table 4) in liquid vehicle (e.g., PBS/DMSO/HFIP). The data also demonstrated that the vaccine is capable of stimulating a *de novo* immune response to HCMV in a HCMV-naïve mouse.

25 Example 13. Additional HCMV pp65 CTL Epitopes Specific for HLA A and B Alleles

There are over 100 known HLA Class I alleles of the A and B genes. (J.G. Bodmer et al., *Tissue Antigens* 49:297-321 (1997)). Using a combination of predictive algorithms and truncation analysis, additional peptides from pp65 that sensitize both autologous and allogeneic cells to be lysed by MHC-restricted human CTL were identified. As discussed in Example 1, the CTL arise from HCMV seropositive humans; therefore, the defined epitopes from pp65 were those used by humans to suppress endogenous HCMV reactivation or viremia. To define CTL reactive against HCMV pp65 in combination with specific HLA alleles, individual cloned CTL lines were tested for recognition of EBVLCL infected with pp65vac which contained one of the

HLA A or B alleles found in the individual whose blood was used to derive the CTL. In cases where at least one HLA allele is shared between the EBVLCCL targets and the CTL, sensitization for recognition and lysis was observed. This experiment was repeated with at least three independent cell lines containing the restricting allele. Table 6 shows the pp65 epitopes, their

5 HLA restriction, the number of independent cell lines of the same restriction which were sensitized, and the method(s) of delineation of the epitopes.

Table 6			
HLA A or B Allele Specificity	Number of Test Cell Lines	Method(s) of Determination	Minimal Cytotoxic Epitope Sequence
HLA A*0101 and subtypes	3	A, B, C, D, E	YSEHPTFTSQY (SEQ ID NO:3)
HLA A*6801 and subtypes	3	A, B, D, E	FVFPTKDVALR (SEQ ID NO:5)
HLA B7 and subtypes	5	A, B, D, E	TPRVTGGGAM (SEQ ID NO:7)
HLA B*3502,04, 06 and subtypes	3	A, B, C, D, E	FPTKDVAL (SEQ ID NO:9)
HLA B7 and subtypes	5	A, B, C, E	RPHERNGFTVL (SEQ ID NO:10)
HLA A*1101 and subtypes	5	A, B, C, E	SVLGPISGHVLK (SEQ ID NO:11)
HLA A*0201 and subtypes	5	A, B, C, D, E	NLVPMVATV (SEQ ID NO:1)
HLA B*3801/2	3	A, B, E	PTFTSQYRIQGKL (SEQ ID NO:12)
HLA B*44XX	2	D	EFFWDANDIY (SEQ ID NO:13)
HLA A*2402	4	A, B, E	FTSQYRIQGKL (SEQ ID NO:14)

Methods of Determination: (A) HLA Restriction using single HLA allele matched cell lines; (B) pp65 truncations in vaccinia viruses; (C) pp65 truncations in plasmids with detection of activity using TNF- α assay; (D) matching of amino acid residues using published motifs; (E) functional analysis using ordered overlapping peptides.

5

Example 14. Vaccine Molecules Comprised of More than One CTL Epitope

In accordance with the procedures described herein, vaccines containing a combination of pp150 and/or pp65 epitopes, specific for the same or different HLA Class I restriction elements, were prepared. For vaccination of humans there is no necessity for each epitope to have the same MHC restriction. A vaccine molecule which targets two or more MHC restriction elements may be preferred because it allows the production of fewer vaccine molecules, and still ensures that most HLA alleles were targeted in a polymorphic population. Peptides with CTL epitopes which are restricted by frequently expressed HLA alleles (see Tables 1 and 6) are preferred, and polypeptide vaccines containing epitopes from both the pp65 and pp150 proteins, as well as an HTL epitope, are especially preferred for human vaccination against HCMV. The HLA alleles shown in Tables 1 and 6 are a subset of possible HLA A, B, and C CTL epitopes to be included in a multiple CTL epitope vaccine molecule. The inclusion of multiple CTL epitopes and an HTL epitope will lengthen the peptides (in the range of 40-50 amino acids). Alternatively, HCMV polypeptide vaccines may be prepared without a covalently attached HTL epitope by using multiple CTL epitopes with a spacer of three alanine residues or another combination of amino acids between each epitope, and two palmitic acid-lysyl amides at the N-terminus, as shown in Table 3.

The hydrophobicity of the sequence is an important factor. To reduce hydrophobicity, lipid modification may be omitted. In addition, multiple HLA epitopes may be formulated into a cocktail vaccine. Preferably, each individual CTL epitope in the mixture would be fused to a CD4 T-cell epitope as described above. Thus, the cocktail vaccine could be formulated to contain epitopes sufficient to cover about 75% to about 90% of a multi-ethnic population using the sequences shown in Table 6.

Example 15. Immunization of BMT Patients

A therapeutically active form of an antigenic peptide according to the present invention is administered to an HCMV-seropositive bone marrow transplant donor at a sufficient time (six to eight weeks, for example) in single or multiple doses separated by a given number of days or

weeks prior to bone marrow transplant to enable the development of an anti-HCMV cellular immune response. The antigenic peptide can be formulated in *per se* known manners (for example, as a lipidated peptide, optionally in combination with a helper peptide and/or an adjuvant) and will be administered, preferably, in multiple doses. Peptides in which the helper peptide and antigenic peptide are linked together in one sequence, for example are suitable for this purpose.

An additional vaccine regimen consists of priming a donor with a modified Vaccinia Ankara (MVA) containing a polynucleotide viral vaccine, for example, full-length pp65, pp65 fragments or one or more of the CTL epitopes shown in Table 6, followed by boosting with a peptide vaccine as described in Examples 12 and 14. Those of skill in the art are fully able to devise schemes for vaccination using various combinations of peptide and virus administration, and these variations are contemplated for use with the present invention. If an unmanipulated BMT graft will be given to the recipient, such a graft will contain 25% or more of mature T cells. The T cells confer active immunity to the BMT recipient patient. Alternatively, when a T-cell depleted BMT graft is to be employed, an aliquot of T cells from the immunized donor can be administered to the patient following (for example, approximately 21 to 35 days) BMT to provide the recipient patient with HCMV immunity.

Example 16. In Vitro Assay For HCMV Infected Cells

The peptides of the present invention are used in an *in vitro* assay to detect the presence or absence of HCMV-infected cells obtained, from a patient whose HCMV status (infected or uninfected) is unknown. T lymphocytes obtained from the patient are incubated with antigen presenting cells primed with a peptide of the present invention. The activation of CTL or CTLp reveals that the patient was infected with HCMV.

Example 17. Induction of Immune Response by Vaccination of Transgenic Mice with Unlipidated Peptide

Two HLA-A2.1k^b transgenic mice were inoculated with 100 nmoles of the A2 HCMV pp65 peptide NLVPMVATV (SEQ ID NO:1) in 10% DMSO, 0.1% acetic acid with 20 µg of the T-helper peptide, PADRE (AKXVAAWTLKAAA where X signifies cyclohexylalanine; SEQ ID NO:29), emulsified in a 1:1 ratio with incomplete Freund's adjuvant by sonication for 15-30 seconds. To account for loss during transfer, 300 µL or more excess emulsified vaccine over that required for injections was prepared. The peptide vaccine (100 µL total volume emulsified

preparation above) was injected subcutaneously at the base of the tail, 50 μ L on each side, avoiding the lateral tail veins. Positive control animals were injected in the same manner with the unrelated HLA-A2.1 restricted hu p53₁₁₄₇₋₁₅₇ peptide and PADRE. A booster was administered seven days later. One week after the booster immunization, splenocytes were

5 harvested, cultured, and stimulated *in vitro*. For cultivation, the cells were isolated from the spleens and suspended in 40 mL medium and counted. Erythrocytes were omitted from the counting. The cells were then brought to a concentration of three million cells per milliliter in medium containing 20% Rat-Stim (Collaborative Biomedical Cat #40115, Waltham, MA), and plated at 1 mL/well in 24-well plates. To stimulate the cells, 1 mL suspended antigen-presenting

10 cells (at a ratio of 3 immunized splenocytes to 1 antigen presenting cell) were added to the culture. The cells were incubated at 37°C for seven days. Fresh medium was added as necessary. Stimulations were performed every seven days after plating by addition of 1 mL suspended antigen presenting cells as above.

Antigen presenting cells were prepared as follows. For each immunized group of mice,

15 the spleens of three mice were removed aseptically and suspended at a concentration of 1.0 - 1.5 x 10⁶ cells per mL in RPMI with 10% FCS containing 25 μ g/mL LPS and 7 μ g/mL dextran sulfate for three days at 37°C in 5% CO₂. The cells then were collected, sedimented, resuspended in serum-free medium and counted. Cells were dispensed in volumes containing 25

20 million cells into 15 mL conical centrifuge tubes and gently sedimented at 1200 rpm for six minutes. The supernatant was aspirated, leaving 100 μ L in the tube. Peptide (SEQ ID NO:1) (100 μ M) was added to the tube, mixed well and incubated four hours at 37°C and 5% CO₂. The cells were resuspended in 2 mL complete medium (RPMI 1640 containing 10-12 mM HEPES, 2mM L-glutamine, 100 U/mL penicillin, 100 U/mL streptomycin, 50 μ M β -mercaptoethanol and 10% heat-inactivated fetal calf serum) per tube and concentrated in sterile PBS. The cells were

25 then irradiated with 2500 rads from a ¹³⁷Cs source and then brought to a concentration of 1 million cells per mL in complete medium for use in stimulating the immunized splenocytes.

Six to seven days after *in vitro* stimulation, immunized splenocytes (effector cells) were collected and the cytotoxic activity of the cells was assayed against peptide-loaded or untreated target cells using a ⁵¹Cr release assay. A bulk cell line specific for pp65₄₉₅₋₅₀₃ (SEQ ID NO:1)

30 derived from HLA-A2.1k^b immunized mice and stimulated weekly with the peptide was used as a positive control line. T2 cells were used as targets, either unloaded or loaded with either the peptide of SEQ ID NO:1 or a human control peptide derived from p53. See Example 9. To prepare the targets for the chromium release assay, T2 cells in the log phase of growth were

sedimented and resuspended in 10 mL LCL medium (RPMI 1640 containing 1% HEPES, 10% fetal calf serum, 2% L-glutamine and antibiotics) for each of unloaded or loaded groups. The cells were counted, resedimented, and suspended in 1 mL or less LCL medium. Cells were either unloaded or were loaded with 10 μ l of a 5 mM solution of the appropriate peptide as described above for stimulating antigen-presenting cells. All cells were loaded with 20 μ l ^{51}Cr stock solution containing 10mCi/mL $\text{Na}_2^{51}\text{CrO}_4$. The tubes of cells then were incubated in a 37°C waterbath for 45-60 minutes, shaking gently every 15 minutes. The cells then were washed three times in 10 mL RPMI and resuspended in 1 mL LCL medium. The target cells were recounted and suspended in appropriate volumes of LCL medium to achieve 20,000 cells/mL, and then placed in a 96-well plate at 100 μ L per well.

Effector cells (immunized splenocytes) cells were brought to 2 million cells per mL in RPMI containing 10% FCS and added to the wells containing target cells at different Effector:Target ratios as indicated in FIG. 4. Medium alone (100 μ L) was added to negative control wells to measure spontaneous release of ^{51}Cr , and medium containing 2% sodium dodecyl sulfate (100 μ L) was added to positive control wells to measure total possible release of ^{51}Cr . The plate was subjected to 600 rpm for six minutes with no break in a Sorvall RT7 centrifuge (Kendro Laboratory Products; Newtown, CT) and incubated for four hours at 37°C and 5% CO_2 , then resedimented for six minutes at 1200 rpm. The supernatants then were harvested and the radioactivity measured with a Packard Cobra II gamma counter (Packard Instruments; Meriden, CT). Specific CTL activity was calculated as follows:

$$\% \text{ specific release} = 100 \times \frac{(\text{experimental release} - \text{spontaneous release})}{(\text{total release} - \text{spontaneous release})}$$

Experiments in which spontaneous release was 30% or greater of maximum total release were discarded. FIG. 4A shows results after one *in vitro* stimulation, FIG. 4B shows results after two *in vitro* stimulations, and FIG. 4C shows results after four *in vitro* stimulations. In this figure and those which follow, "T2 A2 pulsed" indicates cells presenting the peptide of SEQ ID NO:1, "T2 p53 pulsed" indicates cells presenting the human control peptide p53₁₄₉₋₁₅₇. The data showed that the vaccination with the inventive peptide vaccine did result in specific CTLs which could recognize and kill appropriate targets. Results improved with a second *in vitro* stimulation.

Example 18. Comparison of Lipidated Vaccine Formulations

Mice were vaccinated as described in Example 17 with four different formulations of a vaccine containing (Pam)₂ - KSSAKXVAAWTLKAAANLVPMVATV wherein X signifies cyclohexylalanine (SEQ ID NO:37). Splenocytes were assayed. Effector-to-target ratios in the chromium release assays were as indicated in FIG. 5, where the results are shown. FIG. 5A provides results for mice inoculated with 100 nmoles peptide in a solution containing 99.9% DMSO and 0.1% formic acid. FIG. 5B shows data for mice vaccinated with 100 nmoles peptide suspended in a vehicle containing 50% DMSO, 49.9% PBS and 0.1% formic acid. FIG. 5C refers to mice injected with 83.3 nmoles peptide dissolved in 41.7% DMSO, 57.7% PBS and 0.6% formic acid. FIG. 5D provides results for mice injected with 83.3 nmoles peptide suspended in 66.7% DMSO, 26.7% acetic acid and 6.7% Tween 20. The 99.9% DMSO solution vaccine provided mice splenocytes having the greatest cytotoxicity versus control.

Example 19. Vaccination of Transgenic Mice with Monolipidated Vaccine Containing PADRE

Mice were vaccinated and the cells assayed as described above with increasing amounts of (Pam)₂ - KSSAKXVAAWTLKAAANLVPMVATV (wherein X signifies cyclohexylalanine (SEQ ID NO:37). The peptide was provided in a solution in 80% DMSO, 20% PBS and 0.08% formic acid in the amounts shown in FIG. 6. Vaccination with 100 or 150 nmoles peptide resulted in potent specific cytotoxicity, with 150 nmoles providing superior results.

Example 20. Specificity of Cytotoxicity

Mice were vaccinated as described above with 150 or 25 nmoles of the peptide of SEQ ID NO:37 formulated as in Example 19. Splenocytes were assayed for cytotoxicity of T2 cells pulsed with and presenting several different peptides. See FIG. 7. "T2 177 pulsed" indicates cells presenting the amidated peptide of SEQ ID NO:39 (NLVPMVATV-NH₂); and "T2 118 pulsed" indicates cells presenting the amidated peptide of SEQ ID NO:40 (YLVPMTASV-NH₂). "T2 193 pulsed" indicates cells presenting the amidated peptide of SEQ ID NO:41 (YLVPMTATV-NH₂). The results showed a high degree of specificity.

Example 21. Comparative Data for Monolipidated Vaccine in Different DMSO Formulations

Mice were immunized and their splenocytes assayed as described in Example 17 with 100 or 150 nmoles SEQ ID NO:37 in vehicles containing different DMSO concentrations. See FIG. 8 for the results of chromium release assays. FIG. 8A: 100 nmoles in 80% DMSO, 20%

PBS and 0.08% formic acid; FIG. 8B: 100 nmoles in 80% DMSO, 60% PBS and 0.04% formic acid; FIG. 8C: 150 nmoles in 80% DMSO, 20% PBS and 0.08% formic acid; FIG. 8D: 150 nmoles in 40% DMSO, 60% PBS and 0.04% formic acid. Formulations of the monolipidated vaccines were more potent when provided in sufficient DMSO concentration to completely solubilize the vaccine peptide. Without wishing to be bound by theory, it is believed that concentrations of DMSO which result in complete solubility of the lipidated peptide vaccines provide superior results.

Example 22. Vaccination Experiments with Differing DMSO Concentrations

Mice were immunized and their splenocytes assayed as described in Example 17 with 100 nmoles SEQ ID NO:37 in the following vehicles containing decreasing amounts of DMSO. FIG. 9A: 80% DMSO, 20% PBS and 0.02% formic acid; FIG. 9B: 70% DMSO, 30% PBS and 0.07% formic acid; FIG. 9C: 60% DMSO, 40% PBS and 0.06% formic acid; FIG. 9D: 50% DMSO, 50% PBS and 0.02% formic acid. The formulation for FIG. 9A was a solution and the remaining formulations containing less DMSO were suspensions. The results in FIG. 9D reflect mice which received a booster, whereas the remaining panels of FIG. 9 present data from mice receiving one vaccination only. These data confirm the hypothesis that the vaccine should be fully solubilized for best results.

Example 23. Vaccination Experiments with Different DMSO Concentrations

The method of Example 22 was repeated using the following formulations. FIG. 10A: 80% DMSO, 20% PBS and 0.02% formic acid; FIG. 10B: 70% DMSO, 30% PBS and 0.02% formic acid; FIG. 10C: 60% DMSO, 40% PBS and 0.02% formic acid; FIG. 10D: 50% DMSO, 50% PBS and 0.02% formic acid. As before, the vaccine preparation used to produce the data in FIG. 10A was a solution while the remaining formulations were suspensions. The mice providing the splenocytes assayed in FIG. 10D received a booster immunization.

Example 24. Effect of Booster Immunizations

Mice were immunized and their splenocytes assayed as described in Example 17 using one or two immunizations of 25 or 50 nmoles SEQ ID NO:37. See the results in FIG. 11. FIG. 11A: 50 nmoles; FIG. 11B: 25 nmoles; FIG. 11C: 50 nmoles, plus one booster; FIG. 11D: 50 nmoles, plus one booster. A booster injection increased the cytotoxic effects achieved by the

immunization for the 50 nmole dose, but apparently provided little or no improvement for the 25 nmole dose.

Example 25. Effect of Variable Formic Acid Concentrations

5 Mice were immunized and their splenocytes were assayed as described in Example 17 using one immunization of SEQ ID NO:37 in 80% DMSO, 20% PBS, containing 0.08% formic acid (FIGS. 12A and 12B) or 0.02% formic acid (FIGS. 12C and 12D). The amount of peptide injected was 150 nmoles (FIG. 12A), 100 nmoles (FIG. 12B), 50 nmoles (FIG. 12C) or 25 nmoles (FIG. 12D). Larger doses clearly resulted in higher specific cytotoxicity after
10 vaccination.

Example 26. Vaccination Using Unlipidated Peptide Linked to PADRE

Mice were immunized and their splenocytes assayed as described in Example 17 using one injection of the HCMV peptide of SEQ ID NO:1, directly linked to PADRE to form one
15 sequence (100 nmol; KSSAKXVAAWTLKAAANLVP MVATV wherein X is cyclohexylalanine; SEQ ID NO:37) emulsified with incomplete Freund's adjuvant. The vaccine administered was 100 μ L of an emulsion containing 5% DMSO, 45% normal saline and 50% incomplete Freund's adjuvant. Tested using T2 cells presenting the peptide of SEQ ID NO:1 stimulated twice in the presence of 10% Rat-Stim, the immunized splenocytes exhibited a
20 specific cytotoxicity of 11.22% at an E/T ratio of 100 and 3.18% at an E/T ratio of 20. The immunized splenocytes exhibited an average % cytotoxicity of -4.44% and -0.10% for T2 cells presenting the control p53 peptide, 3.31% and 3.44% for T2 cells presenting the peptide of SEQ ID NO:39, and -6.39% and -1.81% for untreated T2 cells.

25 Example 27. Vaccination Using Unlipidated Linked Peptide in a DNA Adjuvant

Two mice were immunized once with 100 nmoles the peptide of SEQ ID NO:37 with 50 μ g DNA adjuvant containing CpG sequences (positive DNA adjuvant). The DNA sequence used was (1826) 5' TCCATGACGTTCCCTGACGTT 3' (SEQ ID NO:42), as described in Z. Moldoveanu, Vaccine 16(11/12):1216-1224 (1998). The chromium release assay data from these
30 immunized splenocytes are provided below in Table 7.

Example 28. Vaccination Using Unlipidated Linked Peptide in a DNA Adjuvant

Example 27 was repeated using a DNA adjuvant which lacked CpG sequences (negative DNA adjuvant). The DNA sequence used was (1982) 5' TCCAGGACTTCTCTCAGGTT 3' (SEQ ID NO:43), as described in Z. Moldoveanu, Vaccine 16(11/12):1216-1224 (1998). The chromium release assay data are presented below in Table 7.

Table 7. Cytotoxicity of Cells Immunized with Unlipidated Linked Peptide Vaccine in DNA Adjuvant

	Presented Peptide	% Cytotoxicity	
		E/T = 100	E/T = 20
Positive DNA Adjuvant	A2	54.72%	27.79%
	177	13.23%	3.32%
	p53	-4.87%	-2.61%
	untreated	-6.24%	2.77%
Negative DNA Adjuvant	A2	45.57%	18.34%
	177	22.25%	9.55%
	p53	-3.46%	-5.82%
	untreated	1.52%	2.64%

Although certain preferred embodiments and examples of the invention have been described, the invention is not so limited. Persons skilled in this field of science will understand that the present invention is capable of wide application in the fields of diagnostics and therapeutics, and that modifications and variations can be made to the invention without departing from its spirit and scope.

CLAIMS

1. A peptide selected from SEQ ID NOS: 10-25 and 30-41.
2. A vaccine against human cytomegalovirus comprising a peptide having a sequence
5 selected from SEQ ID NOS:1, 10-25 and 30-41 and a pharmaceutically acceptable carrier.
3. A vaccine according to claim 2, which further comprises an adjuvant.
4. A vaccine according to claim 3, wherein said adjuvant is a DNA adjuvant.
10
5. A vaccine according to claim 2, wherein said peptide is unlipidated.
6. A vaccine according to claim 2, wherein said peptide is lipidated.
- 15 7. A vaccine according to claim 6, wherein said peptide is monolipidated.
8. A vaccine according to claim 6, wherein said peptide is dilipidated.
9. A cellular vaccine against human cytomegalovirus comprising antigen presenting cells
20 that have been treated *in vitro* so as to present a peptide according to any one of SEQ ID NOS:1, 10-25 and 30-41.
10. A cellular vaccine according to claim 9, wherein said antigen presenting cells are autologous.
25
11. A cellular vaccine according to claim 9, wherein said antigen presenting cells are allogeneic.
12. A recombinant viral vector vaccine which expresses a gene encoding a peptide according
30 to any one of SEQ ID NOS:1-14, 19, 26-28 and 30.
13. A method of modulating the immune response to human cytomegalovirus infection, comprising administering a vaccine according to any one of claims 2, 3, 4, 9 or 12.

14. A method of modulating the immune response to human cytomegalovirus infection,
comprising administering a vaccine according to claim 2.
15. A method of modulating the immune response to human cytomegalovirus infection,
5 comprising administering a vaccine according to claim 9.
16. A method of modulating the immune response to human cytomegalovirus infection,
comprising administering a vaccine according to claim 12.
- 10 17. A vaccine against human cytomegalovirus comprising a human cytomegalovirus naturally
processed epitope and a DNA adjuvant.
18. A vaccine against human cytomegalovirus comprising a peptide having a the sequence of
SEQ ID NO:1 and a DNA adjuvant.
15
19. A method of modulating the immune response to human cytomegalovirus infection,
comprising administering a vaccine according to claim 4.

1/10




FIG. 1




FIG. 2




FIG. 3

2/10




FIG. 4A




FIG. 4B




FIG. 4C

3/10




FIG. 5B




FIG. 5D




FIG. 5A




FIG. 5C

4/10




FIG. 6B




FIG. 6D




FIG. 6A




FIG. 6C

5/10




FIG. 7B




FIG. 7A

6/10




FIG. 8B




FIG. 8D




FIG. 8A




FIG. 8C

7/10




FIG. 9B




FIG. 9D




FIG. 9A




FIG. 9C

8/10




FIG. 10B




FIG. 10D




FIG. 10A




FIG. 10C

9/10




FIG. 11B




FIG. 11D




FIG. 11A




FIG. 11C




FIG. 12B




FIG. 12D




FIG. 12A




FIG. 12C

SEQUENCE LISTING

<110> Diamond, Don J

<120> Immuno-Reactive Peptide CTL Epitopes of Human Cytomegalovirus

<130> 1954-346PCT

<140>

<141>

<150> US 09/534,639

<151> 2000-03-27

<150> US 09/692,170

<151> 2000-10-20

<160> 44

<170> PatentIn Ver. 2.1

<210> 1

<211> 9

<212> PRT

<213> Human Cytomegalovirus

<400> 1
Asn Leu Val Pro Met Val Ala Thr Val
1 5

<210> 2

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human Cytomegalovirus Peptide Variant

<220>

<221> VARIANT

<222> (2)

<223> X = L, I, M, T or V

<220>

<221> VARIANT

<222> (9)

<223> X = V, A, C, I, L or T

<400> 2
Asn Xaa Val Pro Met Val Ala Thr Xaa
1 5

<210> 3
<211> 11
<212> PRT
<213> Human Cytomegalovirus

<400> 3
Tyr Ser Glu His Pro Thr Phe Thr Ser Gln Tyr
1 5 10

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (2)
<223> X = S, T or L

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<400> 4
Tyr Xaa Glu His Pro Thr Phe Thr Ser Gln Tyr
1 5 10

<210> 5
<211> 11
<212> PRT
<213> Human Cytomegalovirus

<400> 5
Phe Val Phe Pro Thr Lys Asp Val Ala Leu Arg
1 5 10

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<221> VARIANT
<222> (2)
<223> X = V or T

<220>

<221> VARIANT

<222> (9)

<223> X = L, R or K

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<400> 6

Phe Xaa Phe Pro Thr Lys Asp Val Ala Leu Xaa
1 5 10

<210> 7

<211> 10

<212> PRT

<213> Human Cytomegalovirus

<400> 7

Thr Pro Arg Val Thr Gly Gly Gly Ala Met
1 5 10

<210> 8

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<220>

<221> VARIANT

<222> (9)

<223> X = L, F or M

<400> 8

Thr Pro Arg Val Thr Gly Gly Gly Ala Xaa
1 5 10

<210> 9

<211> 8

<212> PRT

<213> Human Cytomegalovirus

<400> 9

Phe Pro Thr Lys Asp Val Ala Leu
1 5

<210> 10
<211> 11
<212> PRT
<213> Human Cytomegalovirus

<400> 10
Arg Pro His Glu Arg Asn Gly Phe Thr Val Leu
1 5 10

<210> 11
<211> 12
<212> PRT
<213> Human Cytomegalovirus

<400> 11
Ser Val Leu Gly Pro Ile Ser Gly His Val Leu Lys
1 5 10

<210> 12
<211> 13
<212> PRT
<213> Human Cytomegalovirus

<400> 12
Pro Thr Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu
1 5 10

<210> 13
<211> 10
<212> PRT
<213> Human Cytomegalovirus

<400> 13
Glu Phe Phe Trp Asp Ala Asn Asp Ile Tyr
1 5 10

<210> 14
<211> 11
<212> PRT
<213> Human Cytomegalovirus

<400> 14
Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu
1 5 10

<210> 15
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>
 <221> MOD_RES
 <222> (4)
 <223> X = cyclohexylalanine

<400> 15
 Ala Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu
 1 5 10 15
 Val Pro Met Val Ala Thr Val
 20

<210> 16
 <211> 23
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>
 <221> MOD_RES
 <222> (1)
 <223> dextro-alanine

<220>
 <221> MOD_RES
 <222> (4)
 <223> X = cyclohexylalanine;

<400> 16
 Ala Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu
 1 5 10 15
 Val Pro Met Val Ala Thr Val
 20

<210> 17
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine;

<400> 17
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu Val
1 5 10 15
Pro Met Val Ala Thr Val
20

<210> 18
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (1)
<223> dextro-alanine

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine;

<400> 18
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu Val
1 5 10 15
Pro Met Val Ala Thr Val
20

<210> 19
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<400> 19
Val Ser Thr Ile Val Pro Tyr Ile Gly Pro Ala Leu Asn Ile Ala Ala
1 5 10 15
Ala Asn Leu Val Pro Met Val Ala Thr Val
20 25

<210> 20
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine;

<220>
<221> MOD_RES
<222> (22)
<223> AMIDATION

<400> 20
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Tyr Leu Val
1 5 10 15
Pro Met Val Ala Thr Val
20

<210> 21
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (1)
<223> dextro-alanine

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine

<220>
<221> MOD_RES
<222> (22)
<223> AMIDATION

<400> 21
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Tyr Leu Val
1 5 10 15
Pro Met Val Ala Thr Val
20

<210> 22
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine;

<220>
<221> MOD_RES
<222> (22)
<223> AMIDATION

<400> 22
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu Val
1 5 10 15
Pro Met Val Ala Thr Val
20

<210> 23
<211> 22
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (3)

<223> X = cyclohexylalanine

<220>

<221> MOD_RES

<222> (22)

<223> AMIDATION

<400> 23

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Tyr Leu Val
1 5 10 15Pro Met Val Ala Ser Val
20

<210> 24

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (3)

<223> X = cyclohexylalanine

<220>

<221> MOD_RES

<222> (22)

<223> AMIDATION

<400> 24

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Asn Leu Leu
1 5 10 15Pro Met Val Ala Ser Val
20

<210> 25

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<221> MOD_RES

<222> (3)

<223> X = cyclohexylalanine

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<400> 25

Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala Ser Val Leu
1 5 10 15Gly Pro Ile Ser Gly His Val Leu Lys
20 25

<210> 26

<211> 10

<212> PRT

<213> Human Cytomegalovirus

<400> 26

Ile Leu Ala Arg Asn Leu Val Pro Met Val
1 5 10

<210> 27

<211> 9

<212> PRT

<213> Human Cytomegalovirus

<400> 27

Glu Leu Glu Gly Val Trp Gln Pro Ala
1 5

<210> 28

<211> 9

<212> PRT

<213> Human Cytomegalovirus

<400> 28

Arg Ile Phe Ala Glu Leu Glu Gly Val
1 5

<210> 29

<211> 13

<212> PRT

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PADRE T Helper Peptide

<220>
<221> MOD_RES
<222> (3)
<223> X = cyclohexylalanine

<400> 29
Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
1 5 10

<210> 30
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human Cytomegalovirus Peptide Vaccine

<400> 30
Lys Ser Ser Asn Leu Val Pro Met Val Ala Thr Val
1 5 10

<210> 31
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human Cytomegalovirus Peptide Vaccine

<220>
<221> MOD_RES
<222> (1)
<223> LIPIDATION: palmitic acid

<400> 31
Lys Ser Ser Asn Leu Val Pro Met Val Ala Thr Val
1 5 10

<210> 32
<211> 12
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 2 palmitic acids

<400> 32

Lys Ser Ser Asn Leu Val Pro Met Val Ala Thr Val
1 5 10

<210> 33

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 2 palmitic acids

<400> 33

Lys Ser Ser Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr
1 5 10 15Glu Ala Ala Ala Asn Leu Val Pro Met Val Ala Thr Val
20 25

<210> 34

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 3 palmitic acids

<400> 34

Cys Ser Ser Gln Tyr Ile Lys Ala Asn Ser Lys Phe Ile Gly Ile Thr
 1 5 10 15

Glu Ala Ala Ala Asn Leu Val Pro Met Val Ala Thr Val
 20 25

<210> 35

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 2 palmitic acids

<220>

<221> VARIANT

<222> (6)

<223> X = cyclohexylalanine or phenylalanine

<400> 35

Lys Ser Ser Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
 1 5 10 15

Gly Gly Gly Asn Leu Val Pro Met Val Ala Thr Val
 20 25

<210> 36

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 3 palmitic acids

<220>

<221> VARIANT

<222> (6)

<223> X = cyclohexylalanine or phenylalanine

<400> 36

Cys Ser Ser Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
 1 5 10 15

Gly Gly Gly Asn Leu Val Pro Met Val Ala Thr Val
 20 25

<210> 37

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 2 palmitic acids

<220>

<221> VARIANT

<222> (6)

<223> X = cyclohexylalanine or phenylalanine

<400> 37

Lys Ser Ser Ala Lys Xaa Val Ala Ala Trp Thr Leu Lys Ala Ala Ala
 1 5 10 15

Asn Leu Val Pro Met Val Ala Thr Val
 20 25

<210> 38

<211> 29

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Human
 Cytomegalovirus Peptide Vaccine

<220>

<221> MOD_RES

<222> (1)

<223> LIPIDATION: 2 palmitic acids

<400> 38

Lys Ser Ser Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn
 1 5 10 15

Glu Ala Ala Ala Asn Leu Val Pro Met Val Ala Thr Val
 20 25

<210> 39
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<220>
<221> MOD_RES
<222> (9)
<223> AMIDATION

<400> 39
Asn Leu Val Pro Met Val Ala Thr Val
1 5

<210> 40
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<220>
<221> MOD_RES
<222> (9)
<223> AMIDATION

<400> 40
Tyr Leu Val Pro Met Val Ala Ser Val
1 5

<210> 41
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Human
Cytomegalovirus Peptide Variant

<220>
<221> MOD_RES
<222> (9)
<223> AMIDATION

<400> 41

Tyr Leu Val Pro Met Val Ala Thr Val
1 5

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Adjuvant

<400> 42

tccatgacgt tcctgacgtt

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA Adjuvant

<400> 43

tccaggactt ctctcaggtt

20

<210> 44

<211> 12

<212> PRT

<213> Human Cytomegalovirus

<400> 44

Thr Phe Thr Ser Gln Tyr Arg Ile Gln Gly Lys Leu
1 5 10

INTERNATIONAL SEARCH REPORT

International Application No

I 'US.01/08576

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/005 A61K39/12 C07K16/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 19349 A (HOPE CITY) 22 April 1999 (1999-04-22) abstract disclosure page 49 examples claim 1	1-17,19

X	WO 97 40165 A (GONCZOL EVA ;WISTAR INST (US); BERENCSI KLARA (US); KARI CSABA (US) 30 October 1997 (1997-10-30) abstract disclosure example 3 figure 5	1-17,19

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 October 2001

Date of mailing of the international search report

08. 2. 02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Panzica, G

INTERNATIONAL SEARCH REPORT

International Application No

US 01/08576

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 00 75180 A (SUREL INGOLF PASCAL ;KERN FLORIAN (DE); KHATAMZAS ELHAM (DE); REIN) 14 December 2000 (2000-12-14) abstract page 27 claim 1	1-17,19
X	--- WO 98 26074 A (DAVIGNON JEAN LUC ;DAVRINCHE CHRISTIAN (FR); INST NAT SANTE RECH M) 18 June 1998 (1998-06-18) the whole document	17
X	--- WO 94 00150 A (HOPE CITY ;ZAIA JOHN A (US); PANDE HEMA (US); RIGGS ARTHUR D (US)) 6 January 1994 (1994-01-06) the whole document	17
X	--- PANDE H ET AL: "HUMAN CYTOMEGALOVIRUS STRAIN TOWNE PP65 GENE NUCLEOTIDE SEQUENCE AND EXPRESSION IN ESCHERICHIA-COLI" VIROLOGY, vol. 182, no. 1, 1991, pages 220-228, XP000561310 ISSN: 0042-6822 the whole document	1-17,19
X	--- PANDE H ET AL: "STRUCTURAL ANALYSIS OF A 64-KDA MAJOR STRUCTURAL PROTEIN OF HUMAN CYTOMEGALOVIRUS TOWNE IDENTIFICATION OF A PHOSPHORYLATION SITE AND COMPARISON TO PP65 OF HCMV AD169" VIROLOGY, vol. 178, no. 1, 1990, pages 6-14, XP001033533 ISSN: 0042-6822 the whole document	1-17,19
X	--- WILLS M R ET AL: "THE HUMAN CYTOTOXIC T-LYMPHOCYTE (CTL) RESPONSE TO CYTOMEGALOVIRUS IS DOMINATED BY STRUCTURAL PROTEIN PP65: FREQUENCY, SPECIFICITY, AND T-CELL RECEPTOR USAGE OF PP65-SPECIFIC CTL" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 11, 1 November 1996 (1996-11-01), pages 7569-7579, XP002060343 ISSN: 0022-538X the whole document -----	17

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/08576

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-17,19 (partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.10 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

2. Claims: 1-19 (partially)

A peptide having sequence as in Seq.d.No.1, and its derivatives, sequences nos.2, 15,16, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

3. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos 3 and 4, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

4. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos.5 and 6, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

5. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.Nos.7 and 8, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

6. Claims: 12, 13, 16 (partially)

A peptide having sequence as in Seq.Id.No.9, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

7. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.11, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

8. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.12, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

9. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.No.13, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

10. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.Id.Nos.14 and 44, and their use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

11. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.17 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

12. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.18 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

13. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.19 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

14. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.20 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

15. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.21 and its use as an immunogenic antigen eliciting immune response against

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

human Cytomegalovirus; compositions and vaccines.

16. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.22 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

17. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.23 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

18. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.24 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

19. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.25 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

20. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.26 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

21. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.27 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

22. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.28 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

23. Claims: 1-17, 19 (partially)

A peptide having sequence as in Seq.d.No.30 and its use as

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

24. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.31 and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

25. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.32, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

26. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.33, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

27. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.34, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

28. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.35, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

29. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.36, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

30. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.37, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

31. Claims: 1-11, 13-17, 19 (partially)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A peptide having sequence as in Seq.d.No.38, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

32. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.39, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

33. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.40, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

34. Claims: 1-11, 13-17, 19 (partially)

A peptide having sequence as in Seq.d.No.41, and its use as an immunogenic antigen eliciting immune response against human Cytomegalovirus; compositions and vaccines.

INTERNATIONAL SEARCH REPORT

International Application No

US 01/08576

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9919349	A	22-04-1999	US 6156317 A	05-12-2000
			AU 7481498 A	03-05-1999
			EP 0946592 A2	06-10-1999
			EP 1023319 A1	02-08-2000
			JP 2001519181 T	23-10-2001
			US 6074645 A	13-06-2000
			WO 9821233 A2	22-05-1998
			WO 9919349 A1	22-04-1999
			US 6251399 B1	26-06-2001

WO 9740165	A	30-10-1997	AU 2809897 A	12-11-1997
			EP 0914441 A2	12-05-1999
			WO 9740165 A1	30-10-1997

WO 0075180	A	14-12-2000	DE 19927039 A1	07-12-2000
			DE 19943702 A1	08-03-2001
			AU 5963500 A	28-12-2000
			WO 0075180 A2	14-12-2000

WO 9826074	A	18-06-1998	FR 2757169 A1	19-06-1998
			AU 5489298 A	03-07-1998
			EP 0951554 A1	27-10-1999
			WO 9826074 A1	18-06-1998
			JP 2001506494 T	22-05-2001

WO 9400150	A	06-01-1994	CA 2117181 A1	06-01-1994
			WO 9400150 A1	06-01-1994
			AU 675204 B2	30-01-1997
			AU 2297292 A	24-01-1994
			DE 69232265 D1	17-01-2002
			EP 0605432 A1	13-07-1994
			JP 6510799 T	01-12-1994
			US 6207161 B1	27-03-2001

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.